Cigna (CI) 10-Q3 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Oct. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38769
Entity Registrant Name	Cigna Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4991898
Entity Address, Address Line One	900 Cottage Grove Road
Entity Address, City or Town	Bloomfield
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06002
City Area Code	860
Local Phone Number	226-6000
Title of 12(b) Security	Common Stock, Par Value $0.01
Trading Symbol	CI
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		305,739,004
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001739940

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Consolidated Statements of Income - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Premiums	$ 9,586	$ 10,275	$ 30,368	$ 30,812
Net investment income	204	468	943	1,169
TOTAL REVENUES	45,280	44,288	134,765	128,390
Benefits and expenses
Pharmacy and other service costs	31,777	30,070	92,740	86,306
Medical costs and other benefit expenses	7,754	8,330	24,214	24,819
Selling, general and administrative expenses	3,148	3,093	9,703	9,368
Amortization of acquired intangible assets	460	501	1,419	1,499
TOTAL BENEFITS AND EXPENSES	43,139	41,994	128,076	121,992
Income from operations	2,141	2,294	6,689	6,398
Interest expense and other	(304)	(303)	(904)	(915)
Debt extinguishment costs	0	0	0	(141)
Gain on sale of businesses	1,735	0	1,735	0
Net realized investment (losses) gains	(81)	68	(495)	128
Income before income taxes	3,491	2,059	7,025	5,470
TOTAL INCOME TAXES	713	424	1,477	1,188
Net income	2,778	1,635	5,548	4,282
Less: Net income attributable to noncontrolling interests	21	14	49	33
SHAREHOLDERS' NET INCOME	$ 2,757	$ 1,621	$ 5,499	$ 4,249
Shareholders' net income per share
Basic (in dollars per share)	$ 9.07	$ 4.84	$ 17.60	$ 12.44
Diluted (in dollars per share)	$ 8.97	$ 4.80	$ 17.42	$ 12.32
Pharmacy revenues
Revenues
Revenues	$ 32,762	$ 31,013	$ 95,431	$ 89,085
Fees and other revenues
Revenues
Revenues	$ 2,728	$ 2,532	$ 8,023	$ 7,324

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 2,778	$ 1,635	$ 5,548	$ 4,282
Other comprehensive income (loss), net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(99)	32	(1,069)	(119)
Net translation gains (losses) on foreign currencies	161	(125)	(108)	(228)
Postretirement benefits liability adjustment	10	16	50	49
Other comprehensive income (loss), net of tax	72	(77)	(1,127)	(298)
Total comprehensive income	2,850	1,558	4,421	3,984
Comprehensive income (loss) attributable to noncontrolling interests
Net income attributable to redeemable noncontrolling interests	3	4	8	12
Net income attributable to other noncontrolling interests	18	10	41	21
Other comprehensive income (loss) attributable to redeemable noncontrolling interests	1	(1)	(2)	(6)
Total comprehensive income attributable to noncontrolling interests	22	13	47	27
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 2,828	$ 1,545	$ 4,374	$ 3,957

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Sep. 30, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 7,079	$ 5,081
Investments		783	920
Accounts receivable, net		17,275	15,071
Inventories		4,017	3,722
Other current assets		1,016	1,283
Assets of businesses held for sale		0	10,057
Total current assets		30,170	36,134
Long-term investments		16,273	18,438
Reinsurance recoverables		4,826	4,970
Deferred policy acquisition costs		764	677
Property and equipment		3,744	3,692
Goodwill		45,807	45,811
Other intangible assets		32,885	34,102
Other assets		2,480	2,728
Separate account assets		7,260	8,337
TOTAL ASSETS		144,209	154,889
Liabilities
Current insurance and contractholder liabilities		6,095	5,318
Pharmacy and other service costs payable		16,676	15,309
Accounts payable		6,870	6,655
Accrued expenses and other liabilities		7,986	7,322
Short-term debt		3,488	2,545
Liabilities of businesses held for sale		0	6,423
Total current liabilities		41,115	43,572
Non-current insurance and contractholder liabilities		11,655	12,563
Deferred tax liabilities, net		7,777	8,346
Other non-current liabilities		3,179	3,762
Long-term debt		28,090	31,125
Separate account liabilities		7,260	8,337
TOTAL LIABILITIES		99,076	107,705
Contingencies — Note 18
Redeemable noncontrolling interests		50	54
Shareholders' equity
Common stock	[1]	4	4
Additional paid-in capital		29,395	29,574
Accumulated other comprehensive loss		(2,009)	(884)
Retained earnings		37,041	32,593
Less: Treasury stock, at cost		(19,390)	(14,175)
TOTAL SHAREHOLDERS' EQUITY		45,041	47,112
Other noncontrolling interests		42	18
Total equity		45,083	47,130
Total liabilities and equity		$ 144,209	$ 154,889

[1]Par value per share, $0.01; shares issued, 397 million as of September 30, 2022 and 394 million as of December 31, 2021; authorized shares, 600 million.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	397,000,000	394,000,000
Common stock, shares authorized (in shares)	600,000,000	600,000,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions	Total	Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2020	$ 50,328	$ 50,321	$ 4	$ 28,975	$ (861)	$ 28,575	$ (6,372)	$ 7
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	417	417		507			(90)
Other comprehensive income (loss)	(292)	(292)			(292)
Net income	4,270	4,249				4,249		21
Common dividends declared	(1,021)	(1,021)				(1,021)
Repurchase of common stock	(6,254)	(6,254)		(400)			(5,854)
Other transactions impacting noncontrolling interests	(21)	(5)		(5)				(16)
Balance at Sep. 30, 2021	47,427	47,415	4	29,077	(1,153)	31,803	(12,316)	12
Balance at Dec. 31, 2020	58
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(6)
Net income	12
Other transactions impacting noncontrolling interests	(8)
Balance at Sep. 30, 2021	56
Balance at Jun. 30, 2021	48,716	48,709	4	29,403	(1,077)	30,513	(10,134)	7
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	75	75		76			(1)
Other comprehensive income (loss)	(76)	(76)			(76)
Net income	1,631	1,621				1,621		10
Common dividends declared	(331)	(331)				(331)
Repurchase of common stock	(2,581)	(2,581)		(400)			(2,181)
Other transactions impacting noncontrolling interests	(7)	(2)		(2)				(5)
Balance at Sep. 30, 2021	47,427	47,415	4	29,077	(1,153)	31,803	(12,316)	12
Balance at Jun. 30, 2021	51
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(1)
Net income	4
Other transactions impacting noncontrolling interests	2
Balance at Sep. 30, 2021	56
Balance at Dec. 31, 2021	47,130	47,112	4	29,574	(884)	32,593	(14,175)	18
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	446	446		521			(75)
Other comprehensive income (loss)	(1,125)	(1,125)			(1,125)
Net income	5,540	5,499				5,499		41
Common dividends declared	(1,051)	(1,051)				(1,051)
Repurchase of common stock	(5,840)	(5,840)		(700)			(5,140)
Other transactions impacting noncontrolling interests	(17)	0		0				(17)
Balance at Sep. 30, 2022	45,083	45,041	4	29,395	(2,009)	37,041	(19,390)	42
Balance at Dec. 31, 2021	54
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(2)
Net income	8
Other transactions impacting noncontrolling interests	(10)
Balance at Sep. 30, 2022	50
Balance at Jun. 30, 2022	45,922	45,892	4	29,930	(2,080)	34,626	(16,588)	30
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	163	163		165			(2)
Other comprehensive income (loss)	71	71			71
Net income	2,775	2,757				2,757		18
Common dividends declared	(342)	(342)				(342)
Repurchase of common stock	(3,500)	(3,500)		(700)			(2,800)
Other transactions impacting noncontrolling interests	(6)	0		0				(6)
Balance at Sep. 30, 2022	45,083	$ 45,041	$ 4	$ 29,395	$ (2,009)	$ 37,041	$ (19,390)	$ 42
Balance at Jun. 30, 2022	45
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	1
Net income	3
Other transactions impacting noncontrolling interests	1
Balance at Sep. 30, 2022	$ 50

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	3 Months Ended							9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 1.12	$ 1.12	$ 1.12	$ 1	$ 1	$ 1	$ 1	$ 3.36	$ 3

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net income		$ 5,548	$ 4,282
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,202	2,180
Realized investment losses (gains), net		495	(128)
Deferred income tax benefit		(300)	(104)
Gain on sale of businesses		(1,735)	0
Debt extinguishment costs		0	141
Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable, net		(2,339)	(4,039)
Inventories		(296)	145
Deferred policy acquisition costs		(127)	(182)
Reinsurance recoverable and Other assets		454	(281)
Insurance liabilities		981	863
Pharmacy and other service costs payable		1,368	1,357
Accounts payable and Accrued expenses and other liabilities		225	(1,411)
Other, net		81	93
NET CASH PROVIDED BY OPERATING ACTIVITIES		6,557	2,916
Proceeds from investments sold:
Debt securities and equity securities		1,406	1,052
Investment maturities and repayments:
Debt securities and equity securities		1,124	1,265
Commercial mortgage loans		73	127
Other sales, maturities and repayments (primarily short-term and other long-term investments)		906	1,261
Investments purchased or originated:
Debt securities and equity securities		(2,457)	(2,742)
Commercial mortgage loans		(84)	(233)
Other (primarily short-term and other long-term investments)		(1,109)	(1,768)
Property and equipment purchases, net		(950)	(850)
Acquisitions, net of cash acquired		0	(1,836)
Divestitures, net of cash sold		4,838	(61)
Other, net		(33)	51
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES		3,714	(3,734)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds		121	132
Withdrawals and benefit payments from contractholder deposit funds		(161)	(139)
Net change in short-term debt		(2,051)	1,633
Payments for debt extinguishment		0	(136)
Repayment of long-term debt		0	(4,578)
Net proceeds on issuance of long-term debt		0	4,260
Repurchase of common stock		(5,874)	(6,321)
Issuance of common stock		317	301
Common stock dividend paid		(1,050)	(1,017)
Other, net		94	24
NET CASH USED IN FINANCING ACTIVITIES		(8,604)	(5,841)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash		(98)	(46)
Net increase (decrease) in cash, cash equivalents and restricted cash		1,569	(6,705)
Cash, cash equivalents and restricted cash January 1,	[1]	5,548
Cash, cash equivalents and restricted cash and cash equivalents January 1,			10,245
Cash, cash equivalents and restricted cash and cash equivalents September 30,	[2]	7,117	3,540
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds		1,346	1,916
Interest paid		$ 923	$ 950

[1]Includes $425 million reported in Assets of businesses held for sale as of January 1, 2022.[2]Restricted cash and cash equivalents were reported in Other long-term investments as of September 30, 2022 and September 30, 2021.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	Dec. 31, 2021 USD ($)
Statement of Cash Flows [Abstract]
Cash, cash equivalents and restricted cash, reported in Assets of businesses held for sale	$ 425

Description of Business

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as "Cigna," the "Company," "we," "our" or "us") is a global health services organization with a mission of helping those we serve improve their health, well-being and peace of mind by making health care affordable, predictable and simple. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and supplemental products and services. The majority of these products are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these ongoing operations, Cigna also has certain run-off operations. Details of the Company's reporting segments and recent changes are provided below: On July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb INA Holdings, Inc. ("Chubb") for approximately $5.4 billion in cash (the "Chubb transaction") (see Notes 4 and 5). During the fourth quarter of 2021, in connection with the Chubb transaction, we revised our business reporting structure and adjusted our segment reporting accordingly. Segment results for the three and nine months ended September 30, 2021 have been restated to conform to the new segment presentation (see Note 19). A full description of our segments follows: Evernorth includes a broad range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits services, specialty pharmacy and care services, which are provided to health plans, employers, government organizations and health care providers. Cigna Healthcare includes U.S. Commercial, U.S. Government and International Health operating segments that provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and self-insured customers. U.S. Government solutions include Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans both on and off the public exchanges. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. Other Operations contains the remainder of our business operations, consisting of the following: • Ongoing business: • Corporate-Owned Life Insurance ("COLI") offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for the purpose of financing employer-paid future benefit obligations. • Exiting businesses: • International Life, Accident and Supplemental Benefits Businesses in six countries sold on July 1, 2022 pursuant to the Chubb transaction. • Our interest in a joint venture in Türkiye: In October 2022, we entered into an agreement to sell our interest to our partner. We are targeting to close the transaction by the end of 2022, subject to applicable regulatory approvals and customary closing conditions. • Run-off businesses: • Reinsurance: predominantly comprised of guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013. • Settlement Annuity and other businesses in run-off. • Individual Life Insurance and Annuity and Retirement Benefits businesses: deferred gains from the sales of these businesses. Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, severance, certain overhead and enterprise-wide project costs and intersegment eliminations for products and services sold between segments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment. Recent Accounting Pronouncements There were no new accounting standards adopted as of September 30, 2022 that had a material impact on our financial statements. There are no accounting pronouncements not yet adopted, with the exception of Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI") that are expected to impact Cigna's operations or our financial statements. Targeted Improvements to the Accounting for Long-Duration Contracts (ASU 2018-12) and related amendments Effective date of January 1, 2023 for Cigna (early adoption permitted) and requires the following key provisions (for insurance entities that issue long-duration contracts): • Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts: • Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) to be updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period Net income. • Discount rate assumptions to be updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed-income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed-income instrument yield is interpreted to mean A-rated. • Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts to be amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. • Market risk benefits (defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk) to be measured at fair value, with changes in fair value recognized in Net income each period, except for the effect of changes in the insurance entity's credit risk to be recognized in other comprehensive income. • Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, separate account liabilities and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement. • Transition methods at adoption vary: • Changes to the liability for future policy benefits to use a modified retrospective approach applied to all outstanding contracts on the basis of their existing carrying amounts as of the beginning of the earliest period presented, with an option to elect a full retrospective transition under certain criteria. Remeasuring the future policy benefits liability for the discount rate to be recorded through Accumulated other comprehensive loss at transition. • DAC to follow the transition method used for future policyholder benefits. • Market risk benefits to be transitioned retrospectively and measured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value to be recognized in the opening balance of retained earnings, excluding the effect of credit risk changes that are to be recognized in Accumulated other comprehensive loss. Expected effects: • The new guidance will apply to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations. • The Company developed a cross-functional implementation project plan and is executing on the necessary changes to our systems, processes and controls. • The Company will adopt the standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and DAC. We currently do not expect the impact of adoption to be material to Shareholders' equity. • While we currently do not expect adoption to result in a material restatement of prior periods, we continue to model the new requirements of the standard and their impacts to financial results across various products. It is possible that our income recognition pattern could change for several reasons: • Applying periodic assumption updates, versus the current locked-in model, may change our timing of profit or loss recognition. • DAC amortization will be on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. • Features, such as the Company's GMDB product, that provide market-risk benefits are not currently measured at fair value, so these liabilities and related reinsurance recoverables will become subject to market sensitivity, notably to interest rates. In July 2022, the Financial Accounting Standards Board ("FASB") issued a proposed standard for comment that would simplify the retrospective adoption of LDTI. The proposal would permit companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. If the FASB approves the proposed standard, Cigna expects to make this policy election for the contracts sold in the Chubb transaction.

Accounts Receivable, Net

Accounts Receivable, Net	9 Months Ended
Accounts Receivable, Net	Sep. 30, 2022
Receivables [Abstract]
Accounts Receivable, Net	Note 3 – Accounts Receivable, Net The following amounts were included within Accounts receivable, net: (In millions) September 30, 2022 December 31, 2021 Noninsurance customer receivables $ 7,544 $ 6,274 Pharmaceutical manufacturers receivables 7,005 5,463 Insurance customer receivables 2,406 2,932 Other receivables 320 456 Total 15,125 Accounts receivable, net classified as Assets of businesses held for sale (54) Accounts receivable, net per Consolidated Balance Sheets $ 17,275 $ 15,071

Mergers, Acquisitions and Dives

Mergers, Acquisitions and Divestitures	9 Months Ended
Mergers, Acquisitions and Divestitures	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Mergers, Acquisitions and Divestitures	Note 4 – Mergers, Acquisitions and Divestitures Divestiture of International BusinessesOn July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for approximately $5.4 billion in cash. The Company recognized a gain of $1.7 billion pre-tax ($1.4 billion after-tax), which includes recognition of previously unrealized capital losses on investments sold and translation loss on foreign currencies (see Note 14 for further information). Also see Note 5 for further information regarding the assets and liabilities of these divested businesses.Acquisition of MDLIVEOn April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. ("MDLIVE"), a 24/7 virtual care platform. Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE. The Company's 2021 Form 10-K includes detailed disclosures of merger consideration, purchase price allocation and intangible assets identified in this transaction. In accordance with GAAP, the total consideration transferred has been allocated to the tangible and intangible net assets acquired based on management's estimates of their fair values and was finalized as of March 31, 2022 with immaterial changes to the purchase price allocation.The results of MDLIVE have been included in the Company's Consolidated Financial Statements from the date of the acquisition. We remain on track and are nearly complete with MDLIVE integration activities. Revenues from MDLIVE and their results of operations were not material to Cigna's consolidated results of operations for the three and nine months ended September 30, 2021. The pro forma effects of this acquisition for prior periods were not material to our consolidated results of operations.Integration and Transaction-related CostsIn the first nine months of 2022 and 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business and the terminated merger with Elevance Health, Inc. ("Elevance"), formerly known as Anthem, Inc. In the first nine months of 2022, the Company also incurred costs related to the Chubb transaction. These costs were $24 million pre-tax ($23 million after-tax) for the three months ended and $112 million pre-tax ($86 million after-tax) for the nine months ended September 30, 2022, compared with $13 million pre-tax ($(35) million after-tax) for the three months ended and $58 million pre-tax ($1 million after-tax) for the nine months ended September 30, 2021. These costs consisted primarily of certain projects to separate or integrate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment-related costs. After-tax costs for the three and nine months ended September 30, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.

Assets and Liabilities of Busin

Assets and Liabilities of Businesses Held for Sale	9 Months Ended
Assets and Liabilities of Businesses Held for Sale	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Business Held for Sale	Note 5 – Assets and Liabilities of Businesses Held for Sale On July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for approximately $5.4 billion in cash. See Note 4 for information on the gain recognized upon sale. The Company aggregated and classified the assets and liabilities of these businesses as held for sale in our Consolidated Balance Sheet as of December 31, 2021. The assets and liabilities of our interest in a joint venture in Türkiye were also classified as held for sale in our Consolidated Balance Sheet as of December 31, 2021; however, we subsequently agreed to exclude this business from the Chubb transaction and the assets and liabilities are no longer classified as held for sale. The assets and liabilities of businesses held for sale were as follows: (In millions) December 31, 2021 Cash and cash equivalents $ 406 Investments 5,109 Deferred policy acquisition costs 2,755 Separate account assets 878 Goodwill, other intangible assets and all other assets 909 Total assets of businesses held for sale 10,057 Insurance and contractholder liabilities 4,644 Accounts payable, accrued expenses and other liabilities 452 Deferred tax liabilities, net 449 Separate account liabilities 878 Total liabilities of businesses held for sale $ 6,423

Earnings Per Share

Earnings Per Share	9 Months Ended
Earnings Per Share	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 6 – Earnings Per Share ("EPS")Basic and diluted earnings per share were computed as follows: Three Months Ended September 30, 2022 September 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 2,757 $ 2,757 $ 1,621 $ 1,621 Shares: Weighted average 303,854 303,854 335,166 335,166 Common stock equivalents 3,663 3,663 2,413 2,413 Total shares 303,854 3,663 307,517 335,166 2,413 337,579 EPS $ 9.07 $ (0.10) $ 8.97 $ 4.84 $ (0.04) $ 4.80 Nine Months Ended September 30, 2022 September 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 5,499 $ 5,499 $ 4,249 $ 4,249 Shares: Weighted average 312,434 312,434 341,583 341,583 Common stock equivalents 3,213 3,213 3,197 3,197 Total shares 312,434 3,213 315,647 341,583 3,197 344,780 EPS $ 17.60 $ (0.18) $ 17.42 $ 12.44 $ (0.12) $ 12.32 The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Anti-dilutive options — 1.5 1.3 1.5 The Company held approximately 91.8 million shares of common stock in treasury at September 30, 2022, 71.2 million shares as of December 31, 2021 and 62.6 million shares as of September 30, 2021. The increase in Treasury stock as of September 30, 2022 and the reduction in weighted average shares outstanding for the three and nine months ended September 30, 2022 was driven in part by 10.4 million shares of our common stock repurchased in July 2022 under the accelerated share repurchase agreements (the "ASR agreements"). Additionally, we expect final settlement of the ASR agreements to occur in the fourth quarter. S ee Note 8 for additional information.

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 7 – Debt The outstanding amounts of debt and finance leases were as follows: (In millions) September 30, 2022 December 31, 2021 Short-term debt Commercial paper $ — $ 2,027 $500 million, 3.05% Notes due November 2022 499 495 $17 million, 8.3% Notes due January 2023 17 — $63 million, 7.65% Notes due March 2023 63 — $700 million, Floating Rate Notes due July 2023 699 — $1,000 million, 3% Notes due July 2023 992 — $1,187 million, 3.75% Notes due July 2023 1,186 — Other, including finance leases 32 23 Total short-term debt $ 3,488 $ 2,545 Long-term debt $17 million, 8.3% Notes due January 2023 $ — $ 17 $63 million, 7.65% Notes due March 2023 — 63 $700 million, Floating Rate Notes due July 2023 — 699 $1,000 million, 3% Notes due July 2023 — 985 $1,187 million, 3.75% Notes due July 2023 — 1,185 $500 million, 0.613% Notes due March 2024 499 498 $1,000 million, 3.5% Notes due June 2024 989 983 $900 million, 3.25% Notes due April 2025 (1) 873 897 $2,200 million, 4.125% Notes due November 2025 2,194 2,193 $1,500 million, 4.5% Notes due February 2026 1,503 1,504 $800 million, 1.25% Notes due March 2026 797 796 $1,500 million, 3.4% Notes due March 2027 1,433 1,423 $259 million, 7.875% Debentures due May 2027 259 259 $600 million, 3.05% Notes due October 2027 596 596 $3,800 million, 4.375% Notes due October 2028 3,784 3,782 $1,500 million, 2.4% Notes due March 2030 1,491 1,490 $1,500 million, 2.375% Notes due March 2031 (1) 1,374 1,500 $45 million, 8.3% Step Down Notes due January 2033 45 45 $190 million, 6.15% Notes due November 2036 190 190 $2,200 million, 4.8% Notes due August 2038 2,192 2,192 $750 million, 3.2% Notes due March 2040 743 743 $121 million, 5.875% Notes due March 2041 119 119 $448 million, 6.125% Notes due November 2041 488 490 $317 million, 5.375% Notes due February 2042 315 315 $1,500 million, 4.8% Notes due July 2046 1,466 1,465 $1,000 million, 3.875% Notes due October 2047 989 988 $3,000 million, 4.9% Notes due December 2048 2,968 2,967 $1,250 million, 3.4% Notes due March 2050 1,236 1,236 $1,500 million, 3.4% Notes due March 2051 1,478 1,477 Other, including finance leases 69 28 Total long-term debt $ 28,090 $ 31,125 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 for further information about the Company's interest rate risk management and these derivative instruments. Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of September 30, 2022, there were no outstanding balances under these revolving credit agreements. In April 2022, Cigna entered into the following revolving credit agreements (the "Credit Agreements"): • a $3.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2027 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. Cigna can borrow up to $3.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. • a $1.0 billion three-year revolving credit agreement that will mature in April 2025 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. Cigna can borrow up to $1.0 billion under the credit agreement for general corporate purposes. • a $1.0 billion 364-day revolving credit agreement that will mature in April 2023. Cigna can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion. Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across all three facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on Cigna's senior unsecured credit ratings. Each of the three facilities is diversified among 22 banks. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition. The Credit Agreements replaced a prior $3.0 billion five-year revolving credit and letter of credit agreement maturing on April 2026; a $1.0 billion three-year revolving credit agreement maturing on April 2024; and a $1.0 billion 364-day revolving credit agreement maturing in April 2022. Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper outstanding balance as of September 30, 2022. Debt Covenants. The Company was in compliance with its debt covenants as of September 30, 2022. Interest Expense. Interest expense on long-term and short-term debt was $317 million for the three months ended and $947 million for the nine months ended September 30, 2022, compared with $312 million for the three months ended and $948 million for the nine months ended September 30, 2021.

Common and Preferred Stock

Common and Preferred Stock	9 Months Ended
Common and Preferred Stock	Sep. 30, 2022
Equity [Abstract]
Common and Preferred Stock	Note 8 – Common and Preferred Stock Dividends In the first nine months of 2022, Cigna declared quarterly cash dividends of $1.12 per share of Cigna common stock. In 2021, Cigna initiated and declared quarterly cash dividends of $1.00 per share of Cigna common stock. The following table provides details of Cigna's dividend payments for the nine months ended September 30: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2022 March 9, 2022 March 24, 2022 $1.12 $357 June 8, 2022 June 23, 2022 $1.12 $352 September 7, 2022 September 22, 2022 $1.12 $341 2021 March 10, 2021 March 25, 2021 $1.00 $345 June 8, 2021 June 23, 2021 $1.00 $342 September 8, 2021 September 23, 2021 $1.00 $330 On October 26, 2022, the Board of Directors declared the fourth quarter cash dividend of $1.12 per share of Cigna common stock to be paid on December 21, 2022 to shareholders of record on December 6, 2022. Cigna currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of Cigna and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant. Accelerated Share Repurchase Agreements As part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements with Mizuho Markets Americas LLC and Morgan Stanley & Co. LLC (collectively, the "Counterparties") to repurchase $3.5 billion of common stock in aggregate. In July 2022, in accordance with the ASR agreements, we remitted $3.5 billion to the Counterparties and received an initial delivery of 10.4 million shares of our common stock. The final number of shares to be received under the ASR agreements is determined based on the daily Volume-Weighted Average Share Price ("VWAP") of our common stock over the term of the agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. We recorded the payments to the Counterparties as a reduction to Total Shareholders' Equity, consisting of a $2.8 billion increase in Treasury stock, which reflects the value of the initial 10.4 million shares received, and a $700 million decrease in Additional paid-in capital, which reflects the value of the stock held back by the Counterparties pending final settlement of the agreement. The $700 million recorded in Additional paid-in capital will be reclassified to Treasury stock upon settlement of the ASR agreements in the fourth quarter of 2022. The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted net income per share on July 1, 2022, the effective date of the ASR agreements.

Insurance and Contractholder Li

Insurance and Contractholder Liabilities	9 Months Ended
Insurance and Contractholder Liabilities	Sep. 30, 2022
Insurance Loss Reserves [Abstract]
Insurance and Contractholder Liabilities	Note 9 – Insurance and Contractholder Liabilities A. Account Balances – Insurance and Contractholder Liabilities The Company's insurance and contractholder liabilities were comprised of the following: September 30, 2022 December 31, 2021 September 30, 2021 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 365 $ 6,563 $ 6,928 $ 352 $ 6,702 $ 7,054 $ 7,079 Future policy benefits 240 4,775 5,015 312 9,194 9,506 9,490 Unearned premiums 1,204 79 1,283 558 418 976 902 Unpaid claims and claim expenses Cigna Healthcare 4,187 63 4,250 4,159 102 4,261 4,325 Other Operations 99 175 274 548 180 728 697 Total 5,929 16,596 22,525 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (611) (4,033) (4,644) Total insurance and contractholder liabilities per Consolidated Balance Sheets $ 6,095 $ 11,655 $ 17,750 $ 5,318 $ 12,563 $ 17,881 $ 22,493 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.8 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of December 31, 2021. Insurance and contractholder liabilities expected to be paid within one year are classified as current. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment for the nine months ended September 30 was as follows: Nine Months Ended (In millions) September 30, 2022 September 30, 2021 Beginning balance $ 4,261 $ 3,695 Less: Reinsurance and other amounts recoverable 261 237 Beginning balance, net 4,000 3,458 Incurred costs related to: Current year 23,431 23,531 Prior years (278) (217) Total incurred 23,153 23,314 Paid costs related to: Current year 19,655 19,737 Prior years 3,450 2,986 Total paid 23,105 22,723 Ending balance, net 4,048 4,049 Add: Reinsurance and other amounts recoverable 202 276 Ending balance $ 4,250 $ 4,325 Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 for additional information on reinsurance. Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions for the nine months ended September 30 were as follows: Nine Months Ended (Dollars in millions) September 30, 2022 September 30, 2021 $ % (1) $ % (2) Actual completion factors $ 81 0.3 % $ 82 0.3 % Medical cost trend 197 0.6 135 0.5 Total favorable variance $ 278 0.9 % $ 217 0.8 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2021. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2020. Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions. Liability balance details. The liability details for unpaid claims and claim expenses are presented in the following table. The liability balance no longer includes the International Health businesses now reported in Cigna Healthcare following our change in segment reporting. The prior year roll forward has been updated to reflect the segment change. (In millions) September 30, 2022 September 30, 2021 Other Operations Our interest in a joint venture in Türkiye and divested international businesses $ 6 $ 430 Other Operations 268 267 Unpaid claims and claim expenses - Other Operations $ 274 $ 697 Activity in the unpaid claims and claim expenses for the divested international businesses and our interest in a joint venture in Türkiye is presented in the following table. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been largely reinsured. Nine Months Ended (In millions) September 30, 2022 (1) September 30, 2021 Beginning balance $ 447 $ 452 Less: Reinsurance 46 45 Beginning balance, net 401 407 Incurred claims related to: Current year 497 746 Prior years 4 (1) Total incurred 501 745 Paid claims related to: Current year 313 526 Prior years 187 211 Total paid 500 737 Foreign currency (28) (31) Divestiture of international businesses (369) — Ending balance, net 5 384 Add: Reinsurance 1 46 Ending balance $ 6 $ 430 (1) Beginning balance includes unpaid claims amounts classified as Liabilities of businesses held for sale. Reinsurance in the table above reflects amounts due from reinsurers related to unpaid claims liabilities. See Note 10 for additional information on reinsurance.

Reinsurance

Reinsurance	9 Months Ended
Reinsurance	Sep. 30, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	Note 10 – Reinsurance The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables. The Company's reinsurance recoverables as of September 30, 2022 are presented in the following table by range of external credit rating and collateral level: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 89 $ 89 BBB- to BBB+ equivalent current credit ratings (1) — — 58 58 Not rated 131 5 30 166 Total recoverables related to ongoing operations (2) 131 5 177 313 Acquisition, disposition or run-off activities A- equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,819 — 2,819 Berkshire Hathaway Life Insurance Company of Nebraska 254 469 — 723 Prudential Retirement Insurance and Annuity (marketed under Empower brand) 142 — — 142 Prudential Insurance Company of America 385 — — 385 Life Insurance Company of North America — 393 — 393 Other 208 20 16 244 Not rated — 12 3 15 Total recoverables related to acquisition, disposition or run-off activities 989 3,713 19 4,721 Total $ 1,120 $ 3,718 $ 196 $ 5,034 Allowance for uncollectible reinsurance (29) Total reinsurance recoverables (2) $ 5,005 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $179 million of current reinsurance recoverables that are reported in Other current assets. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value. The Company entered into an agreement with Berkshire to effectively exit the GMDB and GMIB business via a reinsurance transaction in 2013. Berkshire reinsured 100% of the Company's future claim payments in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.1 billion remaining at September 30, 2022. GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2021 Form 10-K. GMDB The GMDB exposure arises under annuities written by ceding companies that guarantee the benefit received at death. The Company's exposure arises when the guaranteed minimum death benefit exceeds the fair value of the related mutual fund investments at the time of a contractholder's death. The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. As of September 30, 2022, the account value decreased primarily due to unfavorable equity market performance, which resulted in an increase to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) September 30, 2022 December 31, 2021 Account value $ 7,143 $ 9,795 Net amount at risk $ 2,471 $ 1,392 Number of contractholders (estimated) 160,000 170,000 GMIB The Company reinsured contracts with issuers of GMIB products. The Company's exposure represents the excess of a contractually guaranteed amount over the level of variable annuity account values. Payment by the Company depends on the actual account value in the related underlying mutual funds and the level of interest rates when the contractholders elect to receive minimum income payments that can only occur within 30 days of a policy anniversary after the appropriate waiting period. The Company has purchased retrocessional coverage ("GMIB assets") for these contracts including retrocessional coverage from Berkshire. GMIB liabilities totaling $410 million as of September 30, 2022 and $572 million as of December 31, 2021 are classified as Level 3 because fair value inputs are largely unobservable. The GMIB liabilities reflect the Company's credit risk, while the reinsurance recoverable reflects the credit risk of the reinsurers. There were three reinsurers covering 100% of the GMIB exposures as of September 30, 2022 and December 31, 2021 as follows: (In millions) Line of Business Reinsurer September 30, 2022 December 31, 2021 Collateral and Other Terms at September 30, 2022 GMIB Berkshire $ 207 $ 283 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 120 167 Liberty Re (Bermuda) Ltd. 110 151 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 437 $ 601 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments

Investments	9 Months Ended
Investments	Sep. 30, 2022
Investments [Abstract]
Investments	Note 11 – InvestmentsCigna's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 12 for information about the valuation of the Company's investment portfolio. Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2021 Form 10-K. The following table summarizes the Company's investments by category and current or long-term classification: September 30, 2022 December 31, 2021 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 567 $ 9,263 $ 9,830 $ 796 $ 16,162 $ 16,958 Equity securities 67 604 671 — 603 603 Commercial mortgage loans 13 1,557 1,570 40 1,526 1,566 Policy loans — 1,210 1,210 — 1,338 1,338 Other long-term investments — 3,639 3,639 — 3,574 3,574 Short-term investments 136 — 136 428 — 428 Total 1,264 23,203 24,467 Investments classified as assets of businesses held for sale (1) (344) (4,765) (5,109) Investments per Consolidated Balance Sheets $ 783 $ 16,273 $ 17,056 $ 920 $ 18,438 $ 19,358 (1) Investments related to the international life, accident and supplemental benefits businesses that were held for sale as of December 31, 2021. These investments were primarily comprised of debt securities and other long-term investments, and to a lesser extent, equity securities and short-term investments. See Note 4 to the Consolidated Financial Statements for additional information. The amortized cost and fair value by contractual maturity periods for debt securities were as follows at September 30, 2022: (In millions) Amortized Fair Due in one year or less $ 622 $ 596 Due after one year through five years 3,745 3,459 Due after five years through ten years 3,723 3,230 Due after ten years 2,544 2,200 Mortgage and other asset-backed securities 392 345 Total $ 11,026 $ 9,830 Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties. Our allowance for credit losses on debt securities was not material as of September 30, 2022 and December 31, 2021. Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair September 30, 2022 Federal government and agency $ 304 $ — $ 41 $ (12) $ 333 State and local government 43 — — (3) 40 Foreign government 377 — 19 (27) 369 Corporate 9,910 (56) 76 (1,187) 8,743 Mortgage and other asset-backed 392 — — (47) 345 Total $ 11,026 $ (56) $ 136 $ (1,276) $ 9,830 December 31, 2021 Federal government and agency $ 287 $ — $ 101 $ (1) $ 387 State and local government 154 — 17 — 171 Foreign government 2,468 — 194 (46) 2,616 Corporate 12,361 (23) 1,008 (80) 13,266 Mortgage and other asset-backed 505 — 17 (4) 518 Total $ 15,775 $ (23) $ 1,337 $ (131) $ 16,958 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,262 $ (5) $ 720 $ (10) $ 2,967 (1) Net unrealized appreciation for these investments is excluded from Accumulated other comprehensive loss. As of September 30, 2022 net unrealized depreciation for these investments is included in Accumulated other comprehensive loss. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region. The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. September 30, 2022 December 31, 2021 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 6,101 $ 6,959 $ (858) 1,798 $ 2,785 $ 2,861 $ (76) 909 Below investment grade 1,094 1,214 (120) 1,307 561 578 (17) 781 More than one year Investment grade 720 965 (245) 325 382 412 (30) 143 Below investment grade 257 310 (53) 256 162 170 (8) 53 Total $ 8,172 $ 9,448 $ (1,276) 3,686 $ 3,890 $ 4,021 $ (131) 1,886 Equity Securities The following table provides the values of the Company's equity security investments as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 693 $ 210 $ 257 $ 207 Equity securities with no readily determinable fair value 358 461 270 396 Total $ 1,051 $ 671 $ 527 $ 603 Approximately 65% of our investments in equity securities are in the health care sector, consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry. The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio as of September 30, 2022 and December 31, 2021: (Dollars in millions) September 30, 2022 December 31, 2021 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 848 2.21 $ 560 2.18 60% to 79% 565 1.49 883 1.89 80% to 100% 107 1.21 129 1.47 Greater than 100% 63 1.04 — — Allowance for credit losses (13) (6) Total $ 1,570 1.84 59 % $ 1,566 1.96 61 % Other Long-Term Investments Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments: Carrying Value as of (In millions) September 30, 2022 December 31, 2021 Real estate investments $ 1,231 $ 1,152 Securities partnerships 2,091 2,272 Other 317 150 Total $ 3,639 $ 3,574 The gross fair values of our derivative financial instruments are presented in Note 12. Although we may incur a loss if dealers failed to perform under derivative contracts, collateral has been posted to cover substantially all of the net fair value owed to the Company. As of September 30, 2022 and December 31, 2021, the effects of derivative financial instruments used in these individual hedging strategies were not material to the Consolidated Financial Statements. The following table summarizes the types and notional quantity of derivative instruments held by the Company: Notional Value as of (In millions) September 30, 2022 December 31, 2021 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Foreign currency swap contracts $ 1,078 $ 1,081 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 1,500 $ 750 Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. Foreign currency swap contracts $ 460 $ 526 Foreign currency forward contracts (1) $ — $ 1,380 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts (1) $ — $ 720 (1) These instruments were associated with the international life, accident and supplemental benefits businesses that were disposed in the Chubb transaction as discussed in Note 4 to the Consolidated Financial Statements. The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Net realized investment (losses) gains, excluding credit loss expense and asset write-downs $ (65) $ 44 $ (455) $ 114 Credit loss (expense) recoveries (16) 24 (40) 14 Net realized investment (losses) gains, before income taxes $ (81) $ 68 $ (495) $ 128

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 12 – Fair Value Measurements The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level The following table provides information as of September 30, 2022 and December 31, 2021 about the Company's financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of September 30, 2022 As of December 31, 2021 As of September 30, 2022 As of December 31, 2021 As of September 30, 2022 As of December 31, 2021 As of September 30, 2022 As of December 31, 2021 Financial assets at fair value Debt securities Federal government and agency $ 141 $ 147 $ 192 $ 240 $ — $ — $ 333 $ 387 State and local government — — 40 171 — — 40 171 Foreign government — — 369 2,611 — 5 369 2,616 Corporate — — 8,320 12,606 423 660 8,743 13,266 Mortgage and other asset-backed — — 264 418 81 100 345 518 Total debt securities 141 147 9,185 16,046 504 765 9,830 16,958 Equity securities (1) 6 16 204 160 — 31 210 207 Short-term investments — — 131 428 — — 131 428 Derivative assets (2) — — 340 143 — — 340 143 Financial liabilities at fair value Derivative liabilities $ — $ — $ — $ 33 $ — $ — $ — $ 33 (1) Excludes certain equity securities that have no readily determinable fair value. (2) Derivative assets above include $5 million as of September 30, 2022 that are presented in the Short-term investments category disclosed in Note 11. See Note 11 for more information on our Derivative Financial Instruments. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Quantitative Information about Unobservable Inputs The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of September 30, 2022 and December 31, 2021. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions) September 30, 2022 December 31, 2021 Unobservable input September 30, 2022 September 30, 2022 December 31, 2021 Debt securities Corporate and government debt securities $ 422 $ 664 Liquidity 40 - 1290 (320) bps 60 - 1060 (410) bps Mortgage and other asset-backed securities 81 100 Liquidity 60 - 520 (190) bps 60 - 390 (100) bps Other debt securities 1 1 Total Level 3 debt securities $ 504 $ 765 A significant increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement. Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three and nine months ended September 30, 2022 and 2021. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended For the Nine Months Ended (In millions) 2022 2021 2022 2021 Debt and Equity Securities Beginning balance $ 512 $ 854 $ 796 $ 854 Gains (losses) included in Shareholders' net income 4 3 14 (8) (Losses) gains included in Other comprehensive income (loss) (34) 2 (62) (7) Gains (losses) required to adjust future policy benefits for settlement annuities (1) 23 1 — (6) Purchases, sales and settlements Purchases 81 37 157 108 Sales — (36) — (36) Settlements (54) (1) (206) (26) Total purchases, sales and settlements 27 — (49) 46 Transfers into/(out of) Level 3 Transfers into Level 3 6 58 124 181 Transfers out of Level 3 (34) (19) (319) (161) Total transfers into/(out of) Level 3 (28) 39 (195) 20 Ending balance $ 504 $ 899 $ 504 $ 899 Total (losses) included in Shareholders' net income attributable to instruments held at the reporting date $ — $ (3) $ (2) $ (3) Change in unrealized gains or losses included in Other comprehensive income (loss) for assets held at the end of the reporting period $ (33) $ 2 $ (60) $ (8) (1) Amounts do not accrue to shareholders. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income. Gains and losses included in Other comprehensive income (loss), net of tax in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income. Separate Accounts The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fair values of Separate account assets at September 30, 2022 and December 31, 2021 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 Guaranteed separate accounts (See Note 18) $ 195 $ 227 $ 386 $ 276 $ — $ — $ 581 $ 503 Non-guaranteed separate accounts (1) 194 1,130 5,442 6,406 211 334 5,847 7,870 Subtotal $ 389 $ 1,357 $ 5,828 $ 6,682 $ 211 $ 334 6,428 8,373 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 832 842 Total 9,215 Separate account assets of businesses classified as held for sale (2) (878) Separate account assets per Consolidated Balance Sheets $ 7,260 $ 8,337 (1) Non-guaranteed separate accounts include $4.0 billion as of September 30, 2022 and $4.5 billion as of December 31, 2021 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of September 30, 2022 and $0.3 billion as of December 31, 2021. (2) Investments related to the international life, accident and supplemental benefits businesses that were held for sale as of December 31, 2021. See Note 4 to the Consolidated Financial Statements for additional information. . Separate account assets classified in Level 3 primarily support Cigna's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three and nine months ended September 30, 2022 or 2021. Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of September 30, 2022 Redemption Frequency Redemption Notice (In millions) September 30, 2022 December 31, 2021 Securities partnerships $ 475 $ 513 $ 263 Not applicable Not applicable Real estate funds 353 325 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 832 $ 842 $ 263 As of September 30, 2022, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception. Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value. For the nine months ended September 30, 2022 and 2021, impairments recognized requiring these assets to be measured at fair value were not material. Realized investment gains and losses from these observable price changes for the three and nine months ended September 30, 2022 and September 30, 2021 were not material. The following table includes the Company's financial instruments not recorded at fair value, however fair value disclosure is required at September 30, 2022 and December 31, 2021. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy September 30, 2022 December 31, 2021 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,439 $ 1,570 $ 1,598 $ 1,566 Long-term debt, including current maturities, excluding finance leases Level 2 $ 28,411 $ 31,477 $ 35,621 $ 31,593

Variable Interest Entities

Variable Interest Entities	9 Months Ended
Variable Interest Entities	Sep. 30, 2022
Variable Interest Entities [Abstract]
Variable Interest Entities	Note 13 – Variable Interest EntitiesWe perform ongoing qualitative analyses of our involvement with variable interest entities to determine if consolidation is required. The Company determined that it was not a primary beneficiary in any material variable interest entity as of September 30, 2022 or December 31, 2021. The Company's involvement with variable interest entities for which it is not the primary beneficiary has not changed materially from December 31, 2021. For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2021 Form 10-K. The Company has not provided, and does not intend to provide, financial support to any of these variable interest entities in excess of its maximum exposure.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
Accumulated Other Comprehensive Income (Loss)	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 14 – Accumulated Other Comprehensive Income (Loss) ("AOCI") AOCI includes net unrealized (depreciation) appreciation on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (see Note 11), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized. Changes in the components of AOCI were as follows: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Securities and Derivatives Beginning balance $ (285) $ 749 $ 685 $ 900 (Depreciation) appreciation on securities and derivatives (259) 59 (1,505) (113) Tax (expense) benefit (22) (16) 233 9 Net (depreciation) appreciation on securities and derivatives (281) 43 (1,272) (104) Reclassification adjustment for losses included in Shareholders' net income (Gain on sale of businesses) 171 — 171 — Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains) 14 (14) 41 (20) Reclassification adjustment for tax (benefit) expense included in Shareholders' net income (3) 3 (9) 5 Net losses (gains) reclassified from AOCI to Shareholders' net income 182 (11) 203 (15) Other comprehensive (loss) income, net of tax (99) 32 (1,069) (119) Ending balance $ (384) $ 781 $ (384) $ 781 Translation of foreign currencies Beginning balance $ (499) $ (113) $ (233) $ (15) Translation of foreign currencies (105) (118) (345) (216) Tax benefit (expense) 1 (7) (28) (12) Net translation of foreign currencies (104) (125) (373) (228) Reclassification adjustment for losses included in Net income (Gain on sale of businesses) 236 — 236 — Reclassification adjustment for tax expense included in Net income 29 — 29 — Net translation losses reclassified from AOCI to Net income 265 — 265 — Translation of foreign currencies 131 (118) (109) (216) Tax benefit (expense) 30 (7) 1 (12) Other comprehensive income (loss), net of tax 161 (125) (108) (228) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests 1 (1) (2) (6) Shareholders' other comprehensive income (loss), net of tax 160 (124) (106) (222) Ending balance $ (339) $ (237) $ (339) $ (237) Postretirement benefits liability Beginning balance $ (1,296) $ (1,713) $ (1,336) $ (1,746) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 17 21 50 60 Reclassification adjustment for (gains) included in Shareholders' net income (Gain on sale of businesses) (2) — (2) — Reclassification adjustment for settlement (Interest expense and other) — — — 4 Reclassification adjustment for tax (benefit) included in Shareholders' net income (5) (5) (12) (15) Net adjustments reclassified from AOCI to Shareholders' net income 10 16 36 49 Valuation update — — 18 — Tax (expense) — — (4) — Net change due to valuation update — — 14 — Other comprehensive income, net of tax 10 16 50 49 Ending balance $ (1,286) $ (1,697) $ (1,286) $ (1,697)

Organizational Efficiency Plan

Organizational Efficiency Plan	9 Months Ended
Organizational Efficiency Plan	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Organizational Efficiency Plan	Note 15 – Organizational Efficiency Plan During the fourth quarter of 2021, the Company approved a strategic plan to further leverage its ongoing growth to drive operational efficiency through enhancements to organizational structure and increased use of automation and shared services. As a result, during the fourth quarter of 2021, we recognized a charge in Selling, general and administrative expenses of $168 million, pre-tax ($119 million, after-tax) that included $59 million of one-time expenses related to abandonment of leased assets and impairment of property and equipment as well as $109 million of accrued expenses primarily for severance costs related to headcount reductions. As previously anticipated, during the second quarter of 2022, the Company updated our strategic plan and recognized an additional charge in Selling, general and administrative expenses of $22 million, pre-tax ($17 million, after-tax) related to accrued expenses primarily for severance costs. The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities: (In millions) Balance, December 31, 2021 $ 103 2022 payments (65) Second quarter 2022 charge 22 Balance, September 30, 2022 $ 60 We expect most of the accrued liability to be paid by the end of 2023.

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	Note 16 – Leases Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) September 30, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 396 $ 478 Accrued expenses and other liabilities $ 133 $ 159 Other non-current liabilities 368 436 Total operating lease liabilities $ 501 $ 595 Finance leases: Property and equipment, gross $ 147 $ 101 Accumulated depreciation (46) (51) Property and equipment, net $ 101 $ 50 Short-term debt $ 32 $ 23 Long-term debt 69 28 Total finance lease liabilities $ 101 $ 51 (1) Operating leases include $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.
Leases	Note 16 – Leases Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) September 30, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 396 $ 478 Accrued expenses and other liabilities $ 133 $ 159 Other non-current liabilities 368 436 Total operating lease liabilities $ 501 $ 595 Finance leases: Property and equipment, gross $ 147 $ 101 Accumulated depreciation (46) (51) Property and equipment, net $ 101 $ 50 Short-term debt $ 32 $ 23 Long-term debt 69 28 Total finance lease liabilities $ 101 $ 51 (1) Operating leases include $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 17 – Income Taxes Income Tax Expense The 20.4% effective tax rate for the three months ended September 30, 2022 and the 21.0% effective tax rate for the nine months ended September 30, 2022 were each lower than the 20.6% rate for the three months ended September 30, 2021 and the 21.7% rate for the nine months ended September 30, 2021. These decreases are driven largely by a foreign tax rate differential, including the impact of the Chubb transaction. As of September 30, 2022, we had approximately $360 million in deferred tax assets ("DTAs") associated with unrealized investment losses that are primarily recorded in Accumulated other comprehensive loss. We have determined that a valuation allowance against the DTAs is not currently required based on the Company's ability to carryback losses and other known investment strategies. We will monitor and evaluate the need for any valuation allowance in the future.

Contingencies and Other Matters

Contingencies and Other Matters	9 Months Ended
Contingencies and Other Matters	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Note 18 – Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A. Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of September 30, 2022, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $420 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of September 30, 2022. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition. B. Certain Other Guarantees The Company had indemnification obligations as of September 30, 2022 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of September 30, 2022. C. Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the nine months ended September 30, 2022. D. Legal and Regulatory Matters The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accruals for the matters discussed below under "Litigation Matters" and "Regulatory Matters" are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation. Litigation Matters Express Scripts Litigation with Elevance . In March 2016, Elevance filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claims it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Elevance and $150 million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $14.8 billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations. On June 10, 2022, Express Scripts filed a Motion for Partial Summary Judgment seeking to limit Elevance's remaining prior authorization claims and a Motion to Exclude certain opinions offered by its experts. Elevance filed its opposition to both motions, and a cross-motion to submit a supplemental expert report, on July 9, 2022. Express Scripts' pending Motions were fully briefed at the end of July 2022. Medicare Advantage. A qui tam action that was filed by a private individual on behalf of the government in the United States District Court for the Southern District of New York in 2017 was unsealed on August 6, 2020. The action asserts claims related to risk adjustment practices arising from certain health exams conducted as part of the Company's Medicare Advantage business. In September 2021, the qui tam action was transferred to the United States District Court for the Middle District of Tennessee. On January 11, 2022, the U.S. Department of Justice ("DOJ") (U.S. Attorney's Offices for the Southern District of New York and the Middle District of Tennessee) filed a motion to partially intervene, which was granted on August 2, 2022. On October 14, 2022, the DOJ filed its complaint-in-intervention alleging that certain diagnoses made during in-home exams were invalid for risk adjustment purposes. Cigna's response is due by December 16, 2022. Regulatory Matters Civil Investigative Demand . The DOJ is conducting industry-wide investigations of Medicare Advantage organizations' risk adjustment practices. For certain Medicare Advantage organizations, including Cigna, those investigations have resulted in litigation (see "Litigation Matters—Medicare Advantage" above). The Company is currently responding to information requests (civil investigative demands) from the DOJ (U.S. Attorney's Office for the Eastern District of Pennsylvania). The Company is cooperating with the DOJ and has responded and continues to respond to its requests.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	Note 19 – Segment Information See Note 1 for a description of our segments, including the segment change effective in the fourth quarter of 2021. Prior year segment information has been adjusted to reflect the segment change and a description of our basis of reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy-related transactions between the Evernorth and Cigna Healthcare segments. The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance. The following tables present the special items recorded by the Company for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended (In millions) September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax After-tax Before-tax After-tax Before-tax Integration and transaction-related costs (benefits) $ 23 $ 24 $ (35) $ 13 $ 86 $ 112 $ 1 $ 58 Charge for organizational efficiency plan — — — — 17 22 — — (Benefits) associated with litigation matters — — — — (20) (28) (21) (27) (Gain) on sale of businesses (1,388) (1,735) — — (1,388) (1,735) — — Debt extinguishment costs — — — — — — 110 141 Total impact from special items $ (1,365) $ (1,711) $ (35) $ 13 $ (1,305) $ (1,629) $ 90 $ 172 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended September 30, 2022 Revenues from external customers $ 34,670 $ 10,328 $ 78 $ — $ 45,076 Intersegment revenues 1,003 667 — (1,670) Net investment income 25 101 75 3 204 Total revenues 35,698 11,096 153 (1,667) 45,280 Net realized investment results from certain equity method investments — 80 — — 80 Adjusted revenues $ 35,698 $ 11,176 $ 153 $ (1,667) $ 45,360 Income (loss) before income taxes $ 1,200 $ 879 $ 1,752 $ (340) $ 3,491 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (17) (1) (4) — (22) Net realized investment losses (1) — 158 3 — 161 Amortization of acquired intangible assets 442 17 1 — 460 Special items Integration and transaction-related costs — — — 24 24 (Gain) on sale of businesses — — (1,735) — (1,735) Pre-tax adjusted income (loss) from operations $ 1,625 $ 1,053 $ 17 $ (316) $ 2,379 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended September 30, 2021 Revenues from external customers $ 32,668 $ 10,283 $ 869 $ — $ 43,820 Intersegment revenues 942 584 — (1,526) Net investment income 4 333 131 — 468 Total revenues 33,614 11,200 1,000 (1,526) 44,288 Net realized investment results from certain equity method investments — 22 — — 22 Adjusted revenues $ 33,614 $ 11,222 $ 1,000 $ (1,526) $ 44,310 Income (loss) before income taxes $ 1,074 $ 1,110 $ 196 $ (321) $ 2,059 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (10) (1) (5) — (16) Net realized investment (gains) losses (1) — (73) 27 — (46) Amortization of acquired intangible assets 484 10 7 — 501 Special items Integration and transaction-related costs — — — 13 13 Pre-tax adjusted income (loss) from operations $ 1,548 $ 1,046 $ 225 $ (308) $ 2,511 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Nine months ended September 30, 2022 Revenues from external customers $ 100,675 $ 31,411 $ 1,736 $ — $ 133,822 Intersegment revenues 3,421 1,815 — (5,236) Net investment income 51 545 344 3 943 Total revenues 104,147 33,771 2,080 (5,233) 134,765 Net realized investment results from certain equity method investments — 134 — — 134 Adjusted revenues $ 104,147 $ 33,905 $ 2,080 $ (5,233) $ 134,899 Income (loss) before income taxes $ 3,114 $ 2,943 $ 2,134 $ (1,166) $ 7,025 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (41) (2) (11) — (54) Net realized investment losses (1) — 542 87 — 629 Amortization of acquired intangible assets 1,329 89 1 — 1,419 Special items Integration and transaction-related costs — — — 112 112 Charge for organizational efficiency plan — — — 22 22 (Benefits) associated with litigation matters — — — (28) (28) (Gain) on sale of businesses — — (1,735) — (1,735) Pre-tax adjusted income (loss) from operations $ 4,402 $ 3,572 $ 476 $ (1,060) $ 7,390 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Nine months ended September 30, 2021 Revenues from external customers $ 93,640 $ 30,971 $ 2,610 $ — $ 127,221 Intersegment revenues 3,174 1,683 — (4,857) Net investment income 12 772 385 — 1,169 Total revenues 96,826 33,426 2,995 (4,857) 128,390 Net realized investment results from certain equity method investments — 12 — — 12 Adjusted revenues $ 96,826 $ 33,438 $ 2,995 $ (4,857) $ 128,402 Income (loss) before income taxes $ 2,752 $ 3,266 $ 630 $ (1,178) $ 5,470 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (21) (2) (16) — (39) Net realized investment losses (gains) (1) 4 (163) 43 — (116) Amortization of acquired intangible assets 1,449 36 14 — 1,499 Special items Integration and transaction-related costs — — — 58 58 (Benefits) associated with litigation matters — — — (27) (27) Debt extinguishment costs — — — 141 141 Pre-tax adjusted income (loss) from operations $ 4,184 $ 3,137 $ 671 $ (1,006) $ 6,986 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Products (Pharmacy revenues) (ASC 606) Network revenues $ 16,583 $ 16,488 $ 48,221 $ 47,792 Home delivery and specialty revenues 15,583 13,796 45,550 39,911 Other revenues 1,630 1,701 5,009 4,708 Intercompany eliminations (1,034) (972) (3,349) (3,326) Total pharmacy revenues 32,762 31,013 95,431 89,085 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 3,821 3,591 11,312 10,692 Stop loss 1,384 1,225 4,053 3,613 Other 353 320 1,065 938 U.S. Government Medicare Advantage 1,949 2,079 6,080 6,287 Medicare Part D 240 315 986 1,175 Other 1,029 1,241 3,007 3,606 International Health 732 646 2,146 1,920 Total Cigna Healthcare 9,508 9,417 28,649 28,231 Divested international businesses — 800 1,500 2,418 Other 76 61 219 169 Intercompany eliminations 2 (3) — (6) Total premiums 9,586 10,275 30,368 30,812 Services (Fees) (ASC 606) Evernorth 1,875 1,623 5,289 4,393 Cigna Healthcare 1,530 1,433 4,504 4,292 Other Operations — 4 9 14 Other revenues (39) 23 108 150 Intercompany eliminations (638) (551) (1,887) (1,525) Total fees and other revenues 2,728 2,532 8,023 7,324 Total revenues from external customers $ 45,076 $ 43,820 $ 133,822 $ 127,221

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted	Recent Accounting Pronouncements There were no new accounting standards adopted as of September 30, 2022 that had a material impact on our financial statements. There are no accounting pronouncements not yet adopted, with the exception of Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI") that are expected to impact Cigna's operations or our financial statements. Targeted Improvements to the Accounting for Long-Duration Contracts (ASU 2018-12) and related amendments Effective date of January 1, 2023 for Cigna (early adoption permitted) and requires the following key provisions (for insurance entities that issue long-duration contracts): • Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts: • Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) to be updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period Net income. • Discount rate assumptions to be updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed-income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed-income instrument yield is interpreted to mean A-rated. • Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts to be amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. • Market risk benefits (defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk) to be measured at fair value, with changes in fair value recognized in Net income each period, except for the effect of changes in the insurance entity's credit risk to be recognized in other comprehensive income. • Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, separate account liabilities and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement. • Transition methods at adoption vary: • Changes to the liability for future policy benefits to use a modified retrospective approach applied to all outstanding contracts on the basis of their existing carrying amounts as of the beginning of the earliest period presented, with an option to elect a full retrospective transition under certain criteria. Remeasuring the future policy benefits liability for the discount rate to be recorded through Accumulated other comprehensive loss at transition. • DAC to follow the transition method used for future policyholder benefits. • Market risk benefits to be transitioned retrospectively and measured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value to be recognized in the opening balance of retained earnings, excluding the effect of credit risk changes that are to be recognized in Accumulated other comprehensive loss. Expected effects: • The new guidance will apply to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations. • The Company developed a cross-functional implementation project plan and is executing on the necessary changes to our systems, processes and controls. • The Company will adopt the standard on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and DAC. We currently do not expect the impact of adoption to be material to Shareholders' equity. • While we currently do not expect adoption to result in a material restatement of prior periods, we continue to model the new requirements of the standard and their impacts to financial results across various products. It is possible that our income recognition pattern could change for several reasons: • Applying periodic assumption updates, versus the current locked-in model, may change our timing of profit or loss recognition. • DAC amortization will be on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. • Features, such as the Company's GMDB product, that provide market-risk benefits are not currently measured at fair value, so these liabilities and related reinsurance recoverables will become subject to market sensitivity, notably to interest rates. In July 2022, the Financial Accounting Standards Board ("FASB") issued a proposed standard for comment that would simplify the retrospective adoption of LDTI. The proposal would permit companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. If the FASB approves the proposed standard, Cigna expects to make this policy election for the contracts sold in the Chubb transaction.
Unpaid Claims and Claims Expenses	This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. This liability includes amounts from the International Health businesses now reported in Cigna Healthcare following our change in segment reporting in 2021. The prior year roll forward has been updated to reflect this segment change.
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 for additional information on reinsuranceThe Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2021 Form 10-K.
Investments	Cigna's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments.Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2021 Form 10-K. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.
Derivative Financial Instruments	The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company has written and purchased GMIB reinsurance contracts in its run-off reinsurance business that are accounted for as freestanding derivatives as discussed in Note 10. Derivatives in the Company's separate accounts are excluded from the following discussion because associated gains and losses generally accrue directly to separate account policyholders. Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments.
Fair Value Measurements	The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income. Gains and losses included in Other comprehensive income (loss), net of tax in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Variable Interest Entities	For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2021 Form 10-K.
Separate Accounts	Separate Accounts The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.
AOCI	AOCI includes net unrealized (depreciation) appreciation on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (see Note 11), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.
Guarantees	Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of September 30, 2022 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.Guaranty Fund AssessmentsThe Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.
Commitment and Contingencies	The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accruals for the matters discussed below under "Litigation Matters" and "Regulatory Matters" are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation.
Segment Information	Intersegment revenues primarily reflect pharmacy-related transactions between the Evernorth and Cigna Healthcare segments.The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.
Revenues and Costs	Evernorth may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	9 Months Ended
Accounts Receivable, Net (Tables)	Sep. 30, 2022
Receivables [Abstract]
Accounts Receivable, Net	The following amounts were included within Accounts receivable, net: (In millions) September 30, 2022 December 31, 2021 Noninsurance customer receivables $ 7,544 $ 6,274 Pharmaceutical manufacturers receivables 7,005 5,463 Insurance customer receivables 2,406 2,932 Other receivables 320 456 Total 15,125 Accounts receivable, net classified as Assets of businesses held for sale (54) Accounts receivable, net per Consolidated Balance Sheets $ 17,275 $ 15,071

Assets and Liabilities of Bus_2

Assets and Liabilities of Businesses Held for Sale (Tables)	9 Months Ended
Assets and Liabilities of Businesses Held for Sale (Tables)	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Business Held for Sale	The assets and liabilities of businesses held for sale were as follows: (In millions) December 31, 2021 Cash and cash equivalents $ 406 Investments 5,109 Deferred policy acquisition costs 2,755 Separate account assets 878 Goodwill, other intangible assets and all other assets 909 Total assets of businesses held for sale 10,057 Insurance and contractholder liabilities 4,644 Accounts payable, accrued expenses and other liabilities 452 Deferred tax liabilities, net 449 Separate account liabilities 878 Total liabilities of businesses held for sale $ 6,423

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
Earnings Per Share (Tables)	Sep. 30, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share were computed as follows: Three Months Ended September 30, 2022 September 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 2,757 $ 2,757 $ 1,621 $ 1,621 Shares: Weighted average 303,854 303,854 335,166 335,166 Common stock equivalents 3,663 3,663 2,413 2,413 Total shares 303,854 3,663 307,517 335,166 2,413 337,579 EPS $ 9.07 $ (0.10) $ 8.97 $ 4.84 $ (0.04) $ 4.80 Nine Months Ended September 30, 2022 September 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 5,499 $ 5,499 $ 4,249 $ 4,249 Shares: Weighted average 312,434 312,434 341,583 341,583 Common stock equivalents 3,213 3,213 3,197 3,197 Total shares 312,434 3,213 315,647 341,583 3,197 344,780 EPS $ 17.60 $ (0.18) $ 17.42 $ 12.44 $ (0.12) $ 12.32
Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share	The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Anti-dilutive options — 1.5 1.3 1.5

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2022
Debt Disclosure [Abstract]
Outstanding Amounts of Debt and Finance Leases	The outstanding amounts of debt and finance leases were as follows: (In millions) September 30, 2022 December 31, 2021 Short-term debt Commercial paper $ — $ 2,027 $500 million, 3.05% Notes due November 2022 499 495 $17 million, 8.3% Notes due January 2023 17 — $63 million, 7.65% Notes due March 2023 63 — $700 million, Floating Rate Notes due July 2023 699 — $1,000 million, 3% Notes due July 2023 992 — $1,187 million, 3.75% Notes due July 2023 1,186 — Other, including finance leases 32 23 Total short-term debt $ 3,488 $ 2,545 Long-term debt $17 million, 8.3% Notes due January 2023 $ — $ 17 $63 million, 7.65% Notes due March 2023 — 63 $700 million, Floating Rate Notes due July 2023 — 699 $1,000 million, 3% Notes due July 2023 — 985 $1,187 million, 3.75% Notes due July 2023 — 1,185 $500 million, 0.613% Notes due March 2024 499 498 $1,000 million, 3.5% Notes due June 2024 989 983 $900 million, 3.25% Notes due April 2025 (1) 873 897 $2,200 million, 4.125% Notes due November 2025 2,194 2,193 $1,500 million, 4.5% Notes due February 2026 1,503 1,504 $800 million, 1.25% Notes due March 2026 797 796 $1,500 million, 3.4% Notes due March 2027 1,433 1,423 $259 million, 7.875% Debentures due May 2027 259 259 $600 million, 3.05% Notes due October 2027 596 596 $3,800 million, 4.375% Notes due October 2028 3,784 3,782 $1,500 million, 2.4% Notes due March 2030 1,491 1,490 $1,500 million, 2.375% Notes due March 2031 (1) 1,374 1,500 $45 million, 8.3% Step Down Notes due January 2033 45 45 $190 million, 6.15% Notes due November 2036 190 190 $2,200 million, 4.8% Notes due August 2038 2,192 2,192 $750 million, 3.2% Notes due March 2040 743 743 $121 million, 5.875% Notes due March 2041 119 119 $448 million, 6.125% Notes due November 2041 488 490 $317 million, 5.375% Notes due February 2042 315 315 $1,500 million, 4.8% Notes due July 2046 1,466 1,465 $1,000 million, 3.875% Notes due October 2047 989 988 $3,000 million, 4.9% Notes due December 2048 2,968 2,967 $1,250 million, 3.4% Notes due March 2050 1,236 1,236 $1,500 million, 3.4% Notes due March 2051 1,478 1,477 Other, including finance leases 69 28 Total long-term debt $ 28,090 $ 31,125 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 for further information about the Company's interest rate risk management and these derivative instruments.

Common and Preferred Stock (Tab

Common and Preferred Stock (Tables)	9 Months Ended
Common and Preferred Stock (Tables)	Sep. 30, 2022
Equity [Abstract]
Dividend Payments	The following table provides details of Cigna's dividend payments for the nine months ended September 30: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2022 March 9, 2022 March 24, 2022 $1.12 $357 June 8, 2022 June 23, 2022 $1.12 $352 September 7, 2022 September 22, 2022 $1.12 $341 2021 March 10, 2021 March 25, 2021 $1.00 $345 June 8, 2021 June 23, 2021 $1.00 $342 September 8, 2021 September 23, 2021 $1.00 $330

Insurance and Contractholder _2

Insurance and Contractholder Liabilities (Tables)	9 Months Ended
Insurance and Contractholder Liabilities (Tables)	Sep. 30, 2022
Insurance Loss Reserves [Abstract]
Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses	The Company's insurance and contractholder liabilities were comprised of the following: September 30, 2022 December 31, 2021 September 30, 2021 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 365 $ 6,563 $ 6,928 $ 352 $ 6,702 $ 7,054 $ 7,079 Future policy benefits 240 4,775 5,015 312 9,194 9,506 9,490 Unearned premiums 1,204 79 1,283 558 418 976 902 Unpaid claims and claim expenses Cigna Healthcare 4,187 63 4,250 4,159 102 4,261 4,325 Other Operations 99 175 274 548 180 728 697 Total 5,929 16,596 22,525 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (611) (4,033) (4,644) Total insurance and contractholder liabilities per Consolidated Balance Sheets $ 6,095 $ 11,655 $ 17,750 $ 5,318 $ 12,563 $ 17,881 $ 22,493 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.8 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of December 31, 2021. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment for the nine months ended September 30 was as follows: Nine Months Ended (In millions) September 30, 2022 September 30, 2021 Beginning balance $ 4,261 $ 3,695 Less: Reinsurance and other amounts recoverable 261 237 Beginning balance, net 4,000 3,458 Incurred costs related to: Current year 23,431 23,531 Prior years (278) (217) Total incurred 23,153 23,314 Paid costs related to: Current year 19,655 19,737 Prior years 3,450 2,986 Total paid 23,105 22,723 Ending balance, net 4,048 4,049 Add: Reinsurance and other amounts recoverable 202 276 Ending balance $ 4,250 $ 4,325 Liability balance details. The liability details for unpaid claims and claim expenses are presented in the following table. The liability balance no longer includes the International Health businesses now reported in Cigna Healthcare following our change in segment reporting. The prior year roll forward has been updated to reflect the segment change. (In millions) September 30, 2022 September 30, 2021 Other Operations Our interest in a joint venture in Türkiye and divested international businesses $ 6 $ 430 Other Operations 268 267 Unpaid claims and claim expenses - Other Operations $ 274 $ 697 Activity in the unpaid claims and claim expenses for the divested international businesses and our interest in a joint venture in Türkiye is presented in the following table. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been largely reinsured. Nine Months Ended (In millions) September 30, 2022 (1) September 30, 2021 Beginning balance $ 447 $ 452 Less: Reinsurance 46 45 Beginning balance, net 401 407 Incurred claims related to: Current year 497 746 Prior years 4 (1) Total incurred 501 745 Paid claims related to: Current year 313 526 Prior years 187 211 Total paid 500 737 Foreign currency (28) (31) Divestiture of international businesses (369) — Ending balance, net 5 384 Add: Reinsurance 1 46 Ending balance $ 6 $ 430
Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses	Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions for the nine months ended September 30 were as follows: Nine Months Ended (Dollars in millions) September 30, 2022 September 30, 2021 $ % (1) $ % (2) Actual completion factors $ 81 0.3 % $ 82 0.3 % Medical cost trend 197 0.6 135 0.5 Total favorable variance $ 278 0.9 % $ 217 0.8 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2021. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2020.

Reinsurance (Tables)

Reinsurance (Tables)	9 Months Ended
Reinsurance (Tables)	Sep. 30, 2022
Reinsurance Disclosures [Abstract]
Reinsurance Recoverables by Range of External Credit Rating and Collateral Level	The Company's reinsurance recoverables as of September 30, 2022 are presented in the following table by range of external credit rating and collateral level: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 89 $ 89 BBB- to BBB+ equivalent current credit ratings (1) — — 58 58 Not rated 131 5 30 166 Total recoverables related to ongoing operations (2) 131 5 177 313 Acquisition, disposition or run-off activities A- equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,819 — 2,819 Berkshire Hathaway Life Insurance Company of Nebraska 254 469 — 723 Prudential Retirement Insurance and Annuity (marketed under Empower brand) 142 — — 142 Prudential Insurance Company of America 385 — — 385 Life Insurance Company of North America — 393 — 393 Other 208 20 16 244 Not rated — 12 3 15 Total recoverables related to acquisition, disposition or run-off activities 989 3,713 19 4,721 Total $ 1,120 $ 3,718 $ 196 $ 5,034 Allowance for uncollectible reinsurance (29) Total reinsurance recoverables (2) $ 5,005 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $179 million of current reinsurance recoverables that are reported in Other current assets. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.
Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death	The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. As of September 30, 2022, the account value decreased primarily due to unfavorable equity market performance, which resulted in an increase to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) September 30, 2022 December 31, 2021 Account value $ 7,143 $ 9,795 Net amount at risk $ 2,471 $ 1,392 Number of contractholders (estimated) 160,000 170,000
Schedule of Derivative Assets at Fair Value	GMIB liabilities totaling $410 million as of September 30, 2022 and $572 million as of December 31, 2021 are classified as Level 3 because fair value inputs are largely unobservable. The GMIB liabilities reflect the Company's credit risk, while the reinsurance recoverable reflects the credit risk of the reinsurers. There were three reinsurers covering 100% of the GMIB exposures as of September 30, 2022 and December 31, 2021 as follows: (In millions) Line of Business Reinsurer September 30, 2022 December 31, 2021 Collateral and Other Terms at September 30, 2022 GMIB Berkshire $ 207 $ 283 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 120 167 Liberty Re (Bermuda) Ltd. 110 151 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 437 $ 601 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments (Tables)

Investments (Tables)	9 Months Ended
Investments (Tables)	Sep. 30, 2022
Investments [Abstract]
Investments by category and current or long-term classification	The following table summarizes the Company's investments by category and current or long-term classification: September 30, 2022 December 31, 2021 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 567 $ 9,263 $ 9,830 $ 796 $ 16,162 $ 16,958 Equity securities 67 604 671 — 603 603 Commercial mortgage loans 13 1,557 1,570 40 1,526 1,566 Policy loans — 1,210 1,210 — 1,338 1,338 Other long-term investments — 3,639 3,639 — 3,574 3,574 Short-term investments 136 — 136 428 — 428 Total 1,264 23,203 24,467 Investments classified as assets of businesses held for sale (1) (344) (4,765) (5,109) Investments per Consolidated Balance Sheets $ 783 $ 16,273 $ 17,056 $ 920 $ 18,438 $ 19,358
Debt Securities by Contractual Maturity	The amortized cost and fair value by contractual maturity periods for debt securities were as follows at September 30, 2022: (In millions) Amortized Fair Due in one year or less $ 622 $ 596 Due after one year through five years 3,745 3,459 Due after five years through ten years 3,723 3,230 Due after ten years 2,544 2,200 Mortgage and other asset-backed securities 392 345 Total $ 11,026 $ 9,830
Gross Unrealized Appreciation (Depreciation) on Debt Securities	Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair September 30, 2022 Federal government and agency $ 304 $ — $ 41 $ (12) $ 333 State and local government 43 — — (3) 40 Foreign government 377 — 19 (27) 369 Corporate 9,910 (56) 76 (1,187) 8,743 Mortgage and other asset-backed 392 — — (47) 345 Total $ 11,026 $ (56) $ 136 $ (1,276) $ 9,830 December 31, 2021 Federal government and agency $ 287 $ — $ 101 $ (1) $ 387 State and local government 154 — 17 — 171 Foreign government 2,468 — 194 (46) 2,616 Corporate 12,361 (23) 1,008 (80) 13,266 Mortgage and other asset-backed 505 — 17 (4) 518 Total $ 15,775 $ (23) $ 1,337 $ (131) $ 16,958 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,262 $ (5) $ 720 $ (10) $ 2,967 (1) Net unrealized appreciation for these investments is excluded from Accumulated other comprehensive loss. As of September 30, 2022 net unrealized depreciation for these investments is included in Accumulated other comprehensive loss.
Summary of Debt Securities with a Decline in Fair Value	The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. September 30, 2022 December 31, 2021 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 6,101 $ 6,959 $ (858) 1,798 $ 2,785 $ 2,861 $ (76) 909 Below investment grade 1,094 1,214 (120) 1,307 561 578 (17) 781 More than one year Investment grade 720 965 (245) 325 382 412 (30) 143 Below investment grade 257 310 (53) 256 162 170 (8) 53 Total $ 8,172 $ 9,448 $ (1,276) 3,686 $ 3,890 $ 4,021 $ (131) 1,886
Equity Security Investments	The following table provides the values of the Company's equity security investments as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 693 $ 210 $ 257 $ 207 Equity securities with no readily determinable fair value 358 461 270 396 Total $ 1,051 $ 671 $ 527 $ 603
Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio	The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio as of September 30, 2022 and December 31, 2021: (Dollars in millions) September 30, 2022 December 31, 2021 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 848 2.21 $ 560 2.18 60% to 79% 565 1.49 883 1.89 80% to 100% 107 1.21 129 1.47 Greater than 100% 63 1.04 — — Allowance for credit losses (13) (6) Total $ 1,570 1.84 59 % $ 1,566 1.96 61 %
Carrying Value Information for Other Long-Term Investments	The following table provides the carrying value information for these investments: Carrying Value as of (In millions) September 30, 2022 December 31, 2021 Real estate investments $ 1,231 $ 1,152 Securities partnerships 2,091 2,272 Other 317 150 Total $ 3,639 $ 3,574
Summary of Derivative Instruments Held	The following table summarizes the types and notional quantity of derivative instruments held by the Company: Notional Value as of (In millions) September 30, 2022 December 31, 2021 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Foreign currency swap contracts $ 1,078 $ 1,081 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 1,500 $ 750 Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. Foreign currency swap contracts $ 460 $ 526 Foreign currency forward contracts (1) $ — $ 1,380 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts (1) $ — $ 720 (1) These instruments were associated with the international life, accident and supplemental benefits businesses that were disposed in the Chubb transaction as discussed in Note 4 to the Consolidated Financial Statements.
Realized Gains and Losses on Investments	The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Net realized investment (losses) gains, excluding credit loss expense and asset write-downs $ (65) $ 44 $ (455) $ 114 Credit loss (expense) recoveries (16) 24 (40) 14 Net realized investment (losses) gains, before income taxes $ (81) $ 68 $ (495) $ 128

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Financial Liabilities Carried at Fair Value	The following table provides information as of September 30, 2022 and December 31, 2021 about the Company's financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of September 30, 2022 As of December 31, 2021 As of September 30, 2022 As of December 31, 2021 As of September 30, 2022 As of December 31, 2021 As of September 30, 2022 As of December 31, 2021 Financial assets at fair value Debt securities Federal government and agency $ 141 $ 147 $ 192 $ 240 $ — $ — $ 333 $ 387 State and local government — — 40 171 — — 40 171 Foreign government — — 369 2,611 — 5 369 2,616 Corporate — — 8,320 12,606 423 660 8,743 13,266 Mortgage and other asset-backed — — 264 418 81 100 345 518 Total debt securities 141 147 9,185 16,046 504 765 9,830 16,958 Equity securities (1) 6 16 204 160 — 31 210 207 Short-term investments — — 131 428 — — 131 428 Derivative assets (2) — — 340 143 — — 340 143 Financial liabilities at fair value Derivative liabilities $ — $ — $ — $ 33 $ — $ — $ — $ 33 (1) Excludes certain equity securities that have no readily determinable fair value. (2) Derivative assets above include $5 million as of September 30, 2022 that are presented in the Short-term investments category disclosed in Note 11. See Note 11 for more information on our Derivative Financial Instruments.
Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities	The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of September 30, 2022 and December 31, 2021. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions) September 30, 2022 December 31, 2021 Unobservable input September 30, 2022 September 30, 2022 December 31, 2021 Debt securities Corporate and government debt securities $ 422 $ 664 Liquidity 40 - 1290 (320) bps 60 - 1060 (410) bps Mortgage and other asset-backed securities 81 100 Liquidity 60 - 520 (190) bps 60 - 390 (100) bps Other debt securities 1 1 Total Level 3 debt securities $ 504 $ 765
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value	The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three and nine months ended September 30, 2022 and 2021. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended For the Nine Months Ended (In millions) 2022 2021 2022 2021 Debt and Equity Securities Beginning balance $ 512 $ 854 $ 796 $ 854 Gains (losses) included in Shareholders' net income 4 3 14 (8) (Losses) gains included in Other comprehensive income (loss) (34) 2 (62) (7) Gains (losses) required to adjust future policy benefits for settlement annuities (1) 23 1 — (6) Purchases, sales and settlements Purchases 81 37 157 108 Sales — (36) — (36) Settlements (54) (1) (206) (26) Total purchases, sales and settlements 27 — (49) 46 Transfers into/(out of) Level 3 Transfers into Level 3 6 58 124 181 Transfers out of Level 3 (34) (19) (319) (161) Total transfers into/(out of) Level 3 (28) 39 (195) 20 Ending balance $ 504 $ 899 $ 504 $ 899 Total (losses) included in Shareholders' net income attributable to instruments held at the reporting date $ — $ (3) $ (2) $ (3) Change in unrealized gains or losses included in Other comprehensive income (loss) for assets held at the end of the reporting period $ (33) $ 2 $ (60) $ (8) (1) Amounts do not accrue to shareholders.
Fair Values of Separate Account Assets	Fair values of Separate account assets at September 30, 2022 and December 31, 2021 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 Guaranteed separate accounts (See Note 18) $ 195 $ 227 $ 386 $ 276 $ — $ — $ 581 $ 503 Non-guaranteed separate accounts (1) 194 1,130 5,442 6,406 211 334 5,847 7,870 Subtotal $ 389 $ 1,357 $ 5,828 $ 6,682 $ 211 $ 334 6,428 8,373 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 832 842 Total 9,215 Separate account assets of businesses classified as held for sale (2) (878) Separate account assets per Consolidated Balance Sheets $ 7,260 $ 8,337 (1) Non-guaranteed separate accounts include $4.0 billion as of September 30, 2022 and $4.5 billion as of December 31, 2021 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of September 30, 2022 and $0.3 billion as of December 31, 2021. (2) Investments related to the international life, accident and supplemental benefits businesses that were held for sale as of December 31, 2021. See Note 4 to the Consolidated Financial Statements for additional information.
Additional Information on Separate Account Assets Priced at NAV	Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of September 30, 2022 Redemption Frequency Redemption Notice (In millions) September 30, 2022 December 31, 2021 Securities partnerships $ 475 $ 513 $ 263 Not applicable Not applicable Real estate funds 353 325 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 832 $ 842 $ 263
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value	The following table includes the Company's financial instruments not recorded at fair value, however fair value disclosure is required at September 30, 2022 and December 31, 2021. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy September 30, 2022 December 31, 2021 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,439 $ 1,570 $ 1,598 $ 1,566 Long-term debt, including current maturities, excluding finance leases Level 2 $ 28,411 $ 31,477 $ 35,621 $ 31,593

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
Accumulated Other Comprehensive Income (Loss) (Tables)	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in the Components of AOCI	Changes in the components of AOCI were as follows: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Securities and Derivatives Beginning balance $ (285) $ 749 $ 685 $ 900 (Depreciation) appreciation on securities and derivatives (259) 59 (1,505) (113) Tax (expense) benefit (22) (16) 233 9 Net (depreciation) appreciation on securities and derivatives (281) 43 (1,272) (104) Reclassification adjustment for losses included in Shareholders' net income (Gain on sale of businesses) 171 — 171 — Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains) 14 (14) 41 (20) Reclassification adjustment for tax (benefit) expense included in Shareholders' net income (3) 3 (9) 5 Net losses (gains) reclassified from AOCI to Shareholders' net income 182 (11) 203 (15) Other comprehensive (loss) income, net of tax (99) 32 (1,069) (119) Ending balance $ (384) $ 781 $ (384) $ 781 Translation of foreign currencies Beginning balance $ (499) $ (113) $ (233) $ (15) Translation of foreign currencies (105) (118) (345) (216) Tax benefit (expense) 1 (7) (28) (12) Net translation of foreign currencies (104) (125) (373) (228) Reclassification adjustment for losses included in Net income (Gain on sale of businesses) 236 — 236 — Reclassification adjustment for tax expense included in Net income 29 — 29 — Net translation losses reclassified from AOCI to Net income 265 — 265 — Translation of foreign currencies 131 (118) (109) (216) Tax benefit (expense) 30 (7) 1 (12) Other comprehensive income (loss), net of tax 161 (125) (108) (228) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests 1 (1) (2) (6) Shareholders' other comprehensive income (loss), net of tax 160 (124) (106) (222) Ending balance $ (339) $ (237) $ (339) $ (237) Postretirement benefits liability Beginning balance $ (1,296) $ (1,713) $ (1,336) $ (1,746) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 17 21 50 60 Reclassification adjustment for (gains) included in Shareholders' net income (Gain on sale of businesses) (2) — (2) — Reclassification adjustment for settlement (Interest expense and other) — — — 4 Reclassification adjustment for tax (benefit) included in Shareholders' net income (5) (5) (12) (15) Net adjustments reclassified from AOCI to Shareholders' net income 10 16 36 49 Valuation update — — 18 — Tax (expense) — — (4) — Net change due to valuation update — — 14 — Other comprehensive income, net of tax 10 16 50 49 Ending balance $ (1,286) $ (1,697) $ (1,286) $ (1,697)

Organizational Efficiency Plan

Organizational Efficiency Plan (Tables)	9 Months Ended
Organizational Efficiency Plan (Tables)	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Rollforward of Accrued Liability	The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities: (In millions) Balance, December 31, 2021 $ 103 2022 payments (65) Second quarter 2022 charge 22 Balance, September 30, 2022 $ 60

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2022
Leases [Abstract]
Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities	Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) September 30, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 396 $ 478 Accrued expenses and other liabilities $ 133 $ 159 Other non-current liabilities 368 436 Total operating lease liabilities $ 501 $ 595 Finance leases: Property and equipment, gross $ 147 $ 101 Accumulated depreciation (46) (51) Property and equipment, net $ 101 $ 50 Short-term debt $ 32 $ 23 Long-term debt 69 28 Total finance lease liabilities $ 101 $ 51 (1) Operating leases include $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Special Items	The following tables present the special items recorded by the Company for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended (In millions) September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax After-tax Before-tax After-tax Before-tax Integration and transaction-related costs (benefits) $ 23 $ 24 $ (35) $ 13 $ 86 $ 112 $ 1 $ 58 Charge for organizational efficiency plan — — — — 17 22 — — (Benefits) associated with litigation matters — — — — (20) (28) (21) (27) (Gain) on sale of businesses (1,388) (1,735) — — (1,388) (1,735) — — Debt extinguishment costs — — — — — — 110 141 Total impact from special items $ (1,365) $ (1,711) $ (35) $ 13 $ (1,305) $ (1,629) $ 90 $ 172
Summarized Segment Financial Information	Summarized segment financial information was as follows: (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended September 30, 2022 Revenues from external customers $ 34,670 $ 10,328 $ 78 $ — $ 45,076 Intersegment revenues 1,003 667 — (1,670) Net investment income 25 101 75 3 204 Total revenues 35,698 11,096 153 (1,667) 45,280 Net realized investment results from certain equity method investments — 80 — — 80 Adjusted revenues $ 35,698 $ 11,176 $ 153 $ (1,667) $ 45,360 Income (loss) before income taxes $ 1,200 $ 879 $ 1,752 $ (340) $ 3,491 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (17) (1) (4) — (22) Net realized investment losses (1) — 158 3 — 161 Amortization of acquired intangible assets 442 17 1 — 460 Special items Integration and transaction-related costs — — — 24 24 (Gain) on sale of businesses — — (1,735) — (1,735) Pre-tax adjusted income (loss) from operations $ 1,625 $ 1,053 $ 17 $ (316) $ 2,379 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended September 30, 2021 Revenues from external customers $ 32,668 $ 10,283 $ 869 $ — $ 43,820 Intersegment revenues 942 584 — (1,526) Net investment income 4 333 131 — 468 Total revenues 33,614 11,200 1,000 (1,526) 44,288 Net realized investment results from certain equity method investments — 22 — — 22 Adjusted revenues $ 33,614 $ 11,222 $ 1,000 $ (1,526) $ 44,310 Income (loss) before income taxes $ 1,074 $ 1,110 $ 196 $ (321) $ 2,059 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (10) (1) (5) — (16) Net realized investment (gains) losses (1) — (73) 27 — (46) Amortization of acquired intangible assets 484 10 7 — 501 Special items Integration and transaction-related costs — — — 13 13 Pre-tax adjusted income (loss) from operations $ 1,548 $ 1,046 $ 225 $ (308) $ 2,511 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Nine months ended September 30, 2022 Revenues from external customers $ 100,675 $ 31,411 $ 1,736 $ — $ 133,822 Intersegment revenues 3,421 1,815 — (5,236) Net investment income 51 545 344 3 943 Total revenues 104,147 33,771 2,080 (5,233) 134,765 Net realized investment results from certain equity method investments — 134 — — 134 Adjusted revenues $ 104,147 $ 33,905 $ 2,080 $ (5,233) $ 134,899 Income (loss) before income taxes $ 3,114 $ 2,943 $ 2,134 $ (1,166) $ 7,025 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (41) (2) (11) — (54) Net realized investment losses (1) — 542 87 — 629 Amortization of acquired intangible assets 1,329 89 1 — 1,419 Special items Integration and transaction-related costs — — — 112 112 Charge for organizational efficiency plan — — — 22 22 (Benefits) associated with litigation matters — — — (28) (28) (Gain) on sale of businesses — — (1,735) — (1,735) Pre-tax adjusted income (loss) from operations $ 4,402 $ 3,572 $ 476 $ (1,060) $ 7,390 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Nine months ended September 30, 2021 Revenues from external customers $ 93,640 $ 30,971 $ 2,610 $ — $ 127,221 Intersegment revenues 3,174 1,683 — (4,857) Net investment income 12 772 385 — 1,169 Total revenues 96,826 33,426 2,995 (4,857) 128,390 Net realized investment results from certain equity method investments — 12 — — 12 Adjusted revenues $ 96,826 $ 33,438 $ 2,995 $ (4,857) $ 128,402 Income (loss) before income taxes $ 2,752 $ 3,266 $ 630 $ (1,178) $ 5,470 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (21) (2) (16) — (39) Net realized investment losses (gains) (1) 4 (163) 43 — (116) Amortization of acquired intangible assets 1,449 36 14 — 1,499 Special items Integration and transaction-related costs — — — 58 58 (Benefits) associated with litigation matters — — — (27) (27) Debt extinguishment costs — — — 141 141 Pre-tax adjusted income (loss) from operations $ 4,184 $ 3,137 $ 671 $ (1,006) $ 6,986
Revenue from External Customers	Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2022 2021 2022 2021 Products (Pharmacy revenues) (ASC 606) Network revenues $ 16,583 $ 16,488 $ 48,221 $ 47,792 Home delivery and specialty revenues 15,583 13,796 45,550 39,911 Other revenues 1,630 1,701 5,009 4,708 Intercompany eliminations (1,034) (972) (3,349) (3,326) Total pharmacy revenues 32,762 31,013 95,431 89,085 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 3,821 3,591 11,312 10,692 Stop loss 1,384 1,225 4,053 3,613 Other 353 320 1,065 938 U.S. Government Medicare Advantage 1,949 2,079 6,080 6,287 Medicare Part D 240 315 986 1,175 Other 1,029 1,241 3,007 3,606 International Health 732 646 2,146 1,920 Total Cigna Healthcare 9,508 9,417 28,649 28,231 Divested international businesses — 800 1,500 2,418 Other 76 61 219 169 Intercompany eliminations 2 (3) — (6) Total premiums 9,586 10,275 30,368 30,812 Services (Fees) (ASC 606) Evernorth 1,875 1,623 5,289 4,393 Cigna Healthcare 1,530 1,433 4,504 4,292 Other Operations — 4 9 14 Other revenues (39) 23 108 150 Intercompany eliminations (638) (551) (1,887) (1,525) Total fees and other revenues 2,728 2,532 8,023 7,324 Total revenues from external customers $ 45,076 $ 43,820 $ 133,822 $ 127,221

Description of Business (Detail

Description of Business (Details) $ in Billions	Jul. 01, 2022 USD ($)
International life, accident, supplemental benefits businesses sold \| Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	$ 5.4

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Noninsurance customer receivables	$ 7,544
Pharmaceutical manufacturers receivables	7,005
Insurance customer receivables	2,406
Other receivables	320
Noninsurance customer receivables		$ 6,274
Pharmaceutical manufacturers receivables		5,463
Insurance customer receivables		2,932
Other receivables		456
Total		15,125
Accounts receivable, net classified as Assets of businesses held for sale		(54)
Accounts receivable, net per Consolidated Balance Sheets	$ 17,275	$ 15,071

Accounts Receivable, Net - Narr

Accounts Receivable, Net - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Allowance for receivables net current	$ 1,700	$ 1,400
Allowance for current expected credit losses on accounts receivable	$ 80	$ 60

Mergers, Acquisitions and Div_2

Mergers, Acquisitions and Divestitures - Narrative (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 01, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Apr. 19, 2021
Business Acquisition [Line Items]
Goodwill		$ 45,807,000,000		$ 45,807,000,000		$ 45,811,000,000
Acquired intangible assets		32,885,000,000		32,885,000,000		$ 34,102,000,000
Integration and transaction-related costs (Selling, general and administrative expenses)		24,000,000	$ 13,000,000	112,000,000	$ 58,000,000
Integration and transaction-related costs, after-tax		$ 23,000,000	$ (35,000,000)	$ 86,000,000	$ 1,000,000
International life, accident, supplemental benefits businesses sold \| Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sale of business, pre-tax	$ 1,700,000,000
Gain (loss) on sale of business, after-tax	$ 1,400,000,000
MDLIVE, Inc.
Business Acquisition [Line Items]
Ownership interest acquired							97%
Ownership interest after acquisition							100%

Assets and Liabilities of Bus_3

Assets and Liabilities of Businesses Held for Sale (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jul. 01, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Separate account assets			$ 878
Assets of businesses held for sale	$ 0		10,057
Insurance and contractholder liabilities			4,644
Total liabilities of businesses held for sale	$ 0		6,423
International life, accident and supplemental benefits businesses \| Held-for-Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents			406
Investments			5,109
Deferred policy acquisition costs			2,755
Separate account assets			878
Goodwill, other intangible assets and all other assets			909
Assets of businesses held for sale			10,057
Insurance and contractholder liabilities			4,644
Accounts payable, accrued expenses and other liabilities			452
Deferred tax liabilities, net			449
Separate account liabilities			878
Total liabilities of businesses held for sale			6,423
Gross unrealized appreciation on securities and derivatives			137
Gross translation loss on foreign currencies			$ 209
International life, accident, supplemental benefits businesses sold \| Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price		$ 5,400

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Shareholders' net income	$ 2,757	$ 1,621	$ 5,499	$ 4,249
Shares:
Weighted average (in shares)	303,854	335,166	312,434	341,583
Common stock equivalents (in shares)	3,663	2,413	3,213	3,197
Total shares (in shares)	307,517	337,579	315,647	344,780
EPS, basic (in dollars per share)	$ 9.07	$ 4.84	$ 17.60	$ 12.44
EPS, effect of dilution (in dollars per share)	(0.10)	(0.04)	(0.18)	(0.12)
EPS, diluted (in dollars per share)	$ 8.97	$ 4.80	$ 17.42	$ 12.32

Earnings Per Share - Outstandin

Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options (in shares)	0	1.5	1.3	1.5

Earnings Per Share - Shares of

Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares shares in Millions	1 Months Ended
	Jul. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Earnings Per Share [Abstract]
Shares of common stock held in treasury		91.8	71.2	62.6
Stock repurchased (in shares)	10.4

Debt - Outstanding Amounts of D

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-term debt
Commercial paper	$ 0	$ 2,027,000,000
Other, including finance leases	32,000,000	23,000,000
Total short-term debt	3,488,000,000	2,545,000,000
Long-term debt
Other, including finance leases	69,000,000	28,000,000
Total long-term debt	28,090,000,000	31,125,000,000
$500 million, 3.05% Notes due November 2022
Short-term debt
Current maturities	499,000,000	495,000,000
Long-term debt
Gross value	$ 500,000,000
Interest Rate	3.05%
$17 million, 8.3% Notes due January 2023
Short-term debt
Current maturities	$ 17,000,000	0
Long-term debt
Long-term debt	0	17,000,000
Gross value	$ 17,000,000
Interest Rate	8.30%
$63 million, 7.65% Notes due March 2023
Short-term debt
Current maturities	$ 63,000,000	0
Long-term debt
Long-term debt	0	63,000,000
Gross value	$ 63,000,000
Interest Rate	7.65%
$700 million, Floating Rate Notes due July 2023
Short-term debt
Current maturities	$ 699,000,000	0
Long-term debt
Long-term debt	0	699,000,000
Gross value	700,000,000
$1,000 million, 3% Notes due July 2023
Short-term debt
Current maturities	992,000,000	0
Long-term debt
Long-term debt	0	985,000,000
Gross value	$ 1,000,000,000
Interest Rate	3%
$1,187 million, 3.75% Notes due July 2023
Short-term debt
Current maturities	$ 1,186,000,000	0
Long-term debt
Long-term debt	0	1,185,000,000
Gross value	$ 1,187,000,000
Interest Rate	3.75%
$500 million, 0.613% Notes due March 2024
Long-term debt
Long-term debt	$ 499,000,000	498,000,000
Gross value	$ 500,000,000
Interest Rate	0.613%
$1,000 million, 3.5% Notes due June 2024
Long-term debt
Long-term debt	$ 989,000,000	983,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.50%
$900 million, 3.25% Notes due April 2025 (1)
Long-term debt
Long-term debt	$ 873,000,000	897,000,000
Gross value	$ 900,000,000
Interest Rate	3.25%
$2,200 million, 4.125% Notes due November 2025
Long-term debt
Long-term debt	$ 2,194,000,000	2,193,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.125%
$1,500 million, 4.5% Notes due February 2026
Long-term debt
Long-term debt	$ 1,503,000,000	1,504,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.50%
$800 million, 1.25% Notes due March 2026
Long-term debt
Long-term debt	$ 797,000,000	796,000,000
Gross value	$ 800,000,000
Interest Rate	1.25%
$1,500 million, 3.4% Notes due March 2027
Long-term debt
Long-term debt	$ 1,433,000,000	1,423,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%
$259 million, 7.875% Debentures due May 2027
Long-term debt
Long-term debt	$ 259,000,000	259,000,000
Gross value	$ 259,000,000
Interest Rate	7.875%
$600 million, 3.05% Notes due October 2027
Long-term debt
Long-term debt	$ 596,000,000	596,000,000
Gross value	$ 600,000,000
Interest Rate	3.05%
$3,800 million, 4.375% Notes due October 2028
Long-term debt
Long-term debt	$ 3,784,000,000	3,782,000,000
Gross value	$ 3,800,000,000
Interest Rate	4.375%
$1,500 million, 2.4% Notes due March 2030
Long-term debt
Long-term debt	$ 1,491,000,000	1,490,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.40%
$1,500 million, 2.375% Notes due 2031
Long-term debt
Long-term debt	$ 1,374,000,000	1,500,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.375%
$45 million, 8.3% Step Down Notes due January 2033
Long-term debt
Long-term debt	$ 45,000,000	45,000,000
Gross value	$ 45,000,000
Interest Rate	8.30%
$190 million, 6.15% Notes due November 2036
Long-term debt
Long-term debt	$ 190,000,000	190,000,000
Gross value	$ 190,000,000
Interest Rate	6.15%
$2,200 million, 4.8% Notes due August 2038
Long-term debt
Long-term debt	$ 2,192,000,000	2,192,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.80%
$750 million, 3.2% Notes due March 2040
Long-term debt
Long-term debt	$ 743,000,000	743,000,000
Gross value	$ 750,000,000
Interest Rate	3.20%
$121 million, 5.875% Notes due March 2041
Long-term debt
Long-term debt	$ 119,000,000	119,000,000
Gross value	$ 121,000,000
Interest Rate	5.875%
$448 million, 6.125% Notes due November 2041
Long-term debt
Long-term debt	$ 488,000,000	490,000,000
Gross value	$ 448,000,000
Interest Rate	6.125%
$317 million, 5.375% Notes due February 2042
Long-term debt
Long-term debt	$ 315,000,000	315,000,000
Gross value	$ 317,000,000
Interest Rate	5.375%
$1,500 million, 4.8% Notes due July 2046
Long-term debt
Long-term debt	$ 1,466,000,000	1,465,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.80%
$1,000 million, 3.875% Notes due October 2047
Long-term debt
Long-term debt	$ 989,000,000	988,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.875%
$3,000 million, 4.9% Notes due December 2048
Long-term debt
Long-term debt	$ 2,968,000,000	2,967,000,000
Gross value	$ 3,000,000,000
Interest Rate	4.90%
$1,250 million, 3.4% Notes due March 2050
Long-term debt
Long-term debt	$ 1,236,000,000	1,236,000,000
Gross value	$ 1,250,000,000
Interest Rate	3.40%
$1,500 million, 3.4% Notes due March 2051
Long-term debt
Long-term debt	$ 1,478,000,000	$ 1,477,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%

Debt - Narrative (Details)

Debt - Narrative (Details)	1 Months Ended		3 Months Ended		9 Months Ended
Debt - Narrative (Details)	Apr. 30, 2022 USD ($) bank	Apr. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Debt Instrument [Line Items]
Interest expense on long-term and short-term debt			$ 317,000,000	$ 312,000,000	$ 947,000,000	$ 948,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity			5,000,000,000		5,000,000,000
Outstanding balances			0		0
Five-year Revolving Credit Agreement, Maturing April 2026
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 3,000,000,000
Credit agreement term		5 years
Three-year Revolving Credit Agreement, Maturing April 2024
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		3 years
364-day Revolving Credit Agreement, Maturing April 2022
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		364 days
Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023
Debt Instrument [Line Items]
Outstanding balances			$ 0		$ 0
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 6,500,000,000
Number of participating banks \| bank	22
Leverage ratio covenant	60%
Revolving Credit And Letter Of Credit Facility Maturing April 2027
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 3,000,000,000
Credit agreement term	5 years
Credit agreement extension term	1 year
Revolving Credit And Letter Of Credit Facility Maturing April 2027 \| Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Revolving Credit Facility Maturing April 2025
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	3 years
Credit agreement extension term	1 year
364 Day Revolving Credit Agreement, Maturing April 2023
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year

Common and Preferred Stock - Na

Common and Preferred Stock - Narrative (Details) - $ / shares		3 Months Ended							9 Months Ended
	Oct. 26, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)		$ 1.12	$ 1.12	$ 1.12	$ 1	$ 1	$ 1	$ 1	$ 3.36	$ 3
Subsequent Event
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)	$ 1.12

Common and Preferred Stock - Di

Common and Preferred Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions							9 Months Ended
	Sep. 22, 2022	Jun. 23, 2022	Mar. 24, 2022	Sep. 23, 2021	Jun. 23, 2021	Mar. 25, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Amount per share (in dollars per share)	$ 1.12	$ 1.12	$ 1.12	$ 1	$ 1	$ 1
Total amount paid	$ 341	$ 352	$ 357	$ 330	$ 342	$ 345	$ 1,050	$ 1,017

Common and Preferred Stock - Ac

Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details) - USD ($) shares in Millions	1 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended
	Jul. 31, 2022	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021
Accelerated Share Repurchases [Line Items]
Accelerated stock repurchase, amount authorized	$ 3,500,000,000
Accelerated stock repurchase, amount remitted	$ 3,500,000,000
Stock repurchased (in shares)	10.4
Stock repurchased			$ 3,500,000,000	$ 2,581,000,000		$ 5,840,000,000	$ 6,254,000,000
Forecast
Accelerated Share Repurchases [Line Items]
Stock repurchased (in shares)		1.9			12.3
Treasury Stock
Accelerated Share Repurchases [Line Items]
Stock repurchased	$ 2,800,000,000		2,800,000,000	2,181,000,000		5,140,000,000	5,854,000,000
Treasury Stock \| Forecast
Accelerated Share Repurchases [Line Items]
Stock repurchased		$ 700,000,000
Additional Paid-in Capital
Accelerated Share Repurchases [Line Items]
Stock repurchased	$ 700,000,000		$ 700,000,000	$ 400,000,000		$ 700,000,000	$ 400,000,000
Additional Paid-in Capital \| Forecast
Accelerated Share Repurchases [Line Items]
Stock repurchased		$ (700,000,000)

Insurance and Contractholder _3

Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Current
Contractholder deposit funds	$ 365	$ 352
Future policy benefits	240
Unearned premiums	1,204
Future policy benefits, including amounts classified as held for sale		312
Unearned premiums, including amounts classified as held for sale		558
Total		5,929
Insurance and contractholder liabilities classified as held for sale		(611)
Current insurance and contractholder liabilities	6,095	5,318
Non-current
Contractholder deposit funds	6,563	6,702
Future policy benefits	4,775
Unearned premiums	79
Future policy benefits, including amounts classified as held for sale		9,194
Unearned premiums, including amounts classified as held for sale		418
Total		16,596
Insurance and contractholder liabilities classified as held for sale		(4,033)
Non-current insurance and contractholder liabilities	11,655	12,563
Total
Contractholder deposit funds	6,928	7,054	$ 7,079
Future policy benefits	5,015		9,490
Unearned premiums	1,283		902
Future policy benefits, including amounts classified as held for sale		9,506
Unearned premiums, including amounts classified as held for sale		976
Total		22,525
Insurance and contractholder liabilities classified as held for sale		(4,644)
Total insurance and contractholder liabilities per Consolidated Balance Sheets	17,750	17,881	22,493
Future policy benefits classified as liabilities of business held for sale		3,800
Unpaid claims classified as liabilities of business held for sale		400
Contractholder deposit funds classified as liabilities of business held for sale		400
Cigna Healthcare
Current
Unpaid claims and claim expenses	4,187
Unpaid claims and claim expenses, including amounts classified as held for sale		4,159
Non-current
Unpaid claims and claim expenses	63
Unpaid claims and claim expenses, including amounts classified as held for sale		102
Total
Unpaid claims and claim expenses	4,250	4,261	4,325	$ 3,695
Unpaid claims and claims expenses, including amounts classified as held for sale		4,261
Other Operations
Current
Unpaid claims and claim expenses	99
Unpaid claims and claim expenses, including amounts classified as held for sale		548
Non-current
Unpaid claims and claim expenses	175
Unpaid claims and claim expenses, including amounts classified as held for sale		180
Total
Unpaid claims and claim expenses	$ 274		$ 697
Unpaid claims and claims expenses, including amounts classified as held for sale		$ 728

Insurance and Contractholder _4

Insurance and Contractholder Liabilities - Narrative (Details) - USD ($) $ in Billions	Sep. 30, 2022	Sep. 30, 2021
Cigna Healthcare
Insurance and Contractholder Liabilities [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process	$ 4	$ 4.1

Insurance and Contractholder _5

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - Cigna Healthcare - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance	$ 4,261	$ 3,695
Less: Reinsurance and other amounts recoverable	261	237
Beginning balance, net	4,000	3,458
Incurred costs related to:
Current year	23,431	23,531
Prior years	(278)	(217)
Total incurred	23,153	23,314
Paid costs related to:
Current year	19,655	19,737
Prior years	3,450	2,986
Total paid	23,105	22,723
Ending balance, net	4,048	4,049
Add: Reinsurance and other amounts recoverable	202	276
Ending balance	$ 4,250	$ 4,325

Insurance and Contractholder _6

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 278	$ 217
Favorable (unfavorable) variance, percentage	0.90%	0.80%
Actual completion factors
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 81	$ 82
Favorable (unfavorable) variance, percentage	0.30%	0.30%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 197	$ 135
Favorable (unfavorable) variance, percentage	0.60%	0.50%

Insurance and Contractholder _7

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Other Operations - Liability Balance Details (Details) - Other Operations - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses		$ 728
Unpaid claims and claim expenses	$ 274		$ 697
Our interest in a joint venture in Türkiye and divested international businesses
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses		$ 447
Unpaid claims and claim expenses			430	$ 452
Interest in Turkiye Joint Venture
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	6
Other Operations
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 268		$ 267

Insurance and Contractholder _8

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Other Operations - Activity (Details) - Other Operations - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance, including disposal groups	$ 728
Paid costs related to:
Ending balance	274	$ 697
Our interest in a joint venture in Türkiye and divested international businesses
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance		452
Less: Reinsurance and other amounts recoverable		45
Beginning balance, net		407
Beginning balance, including disposal groups	447
Less: Reinsurance, including disposal groups	46
Beginning balance, net, including disposal groups	401
Incurred claims related to:
Current year	497	746
Prior years	4	(1)
Total incurred	501	745
Paid costs related to:
Current year	313	526
Prior years	187	211
Total paid	500	737
Foreign currency	(28)	(31)
Divestiture of international businesses		0
Ending balance, net		384
Add: Reinsurance and other amounts recoverable		46
Ending balance		$ 430
Divested international businesses
Paid costs related to:
Divestiture of international businesses	(369)
Interest in Turkiye Joint Venture
Paid costs related to:
Ending balance, net	5
Add: Reinsurance and other amounts recoverable	1
Ending balance	$ 6

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables by Range of External Credit Rating and Collateral Level (Details) $ in Millions	Sep. 30, 2022 USD ($)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 5,034
Allowance for uncollectible reinsurance	(29)
Total reinsurance recoverables	5,005
Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,120
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,718
No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	196
Ongoing Operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables	313
Ongoing Operations \| A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	89
Ongoing Operations \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	58
Ongoing Operations \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	166
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	131
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	131
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	5
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	5
Ongoing Operations \| No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	177
Ongoing Operations \| No collateral \| A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	89
Ongoing Operations \| No collateral \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	58
Ongoing Operations \| No collateral \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	30
Acquisition, disposition or run-off activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables	4,721
Acquisition, disposition or run-off activities \| A- equivalent and higher current ratings ( \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,819
Acquisition, disposition or run-off activities \| A- equivalent and higher current ratings ( \| Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	723
Acquisition, disposition or run-off activities \| A- equivalent and higher current ratings ( \| Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	142
Acquisition, disposition or run-off activities \| A- equivalent and higher current ratings ( \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	385
Acquisition, disposition or run-off activities \| A- equivalent and higher current ratings ( \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	393
Acquisition, disposition or run-off activities \| A- equivalent and higher current ratings ( \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	244
Acquisition, disposition or run-off activities \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	15
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	989
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings ( \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings ( \| Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	254
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings ( \| Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	142
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings ( \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	385
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings ( \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings ( \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	208
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,713
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings ( \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,819
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings ( \| Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	469
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings ( \| Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings ( \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings ( \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	393
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings ( \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	20
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	12
Acquisition, disposition or run-off activities \| No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	19
Acquisition, disposition or run-off activities \| No collateral \| A- equivalent and higher current ratings ( \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| A- equivalent and higher current ratings ( \| Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| A- equivalent and higher current ratings ( \| Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| A- equivalent and higher current ratings ( \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| A- equivalent and higher current ratings ( \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| A- equivalent and higher current ratings ( \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or run-off activities \| No collateral \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 3

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details) $ in Millions	9 Months Ended
Reinsurance - Narrative (Details) $ in Millions	Sep. 30, 2022 USD ($) reinsurer	Dec. 31, 2021 USD ($) reinsurer
GMIB
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100%	100%
Annuitization election period	30 days
Number of external reinsurers \| reinsurer	3	3
GMIB \| Other Contract [Member]
Effects of Reinsurance [Line Items]
GMIB liabilities	$ 410	$ 572
Variable Annuity \| Berkshire Hathaway Life Insurance Company of Nebraska
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100%
Remaining overall limit under reinsurance agreement	$ 3,100
Other Current Assets
Effects of Reinsurance [Line Items]
Reinsurance recoverables	$ 179

Reinsurance - Account Value, Ne

Reinsurance - Account Value, Net Amount at Risk and Contractholders for GMDB Business (Details) - Variable Annuity - GMDB contractholder in Thousands, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) contractholder	Dec. 31, 2021 USD ($) contractholder
Net Amount at Risk by Product and Guarantee [Line Items]
Account value	$ 7,143	$ 9,795
Net amount at risk	$ 2,471	$ 1,392
Number of contractholders (estimated) \| contractholder	160	170

Reinsurance - GMIB Reinsurers (

Reinsurance - GMIB Reinsurers (Details) - GMIB - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Berkshire \| Secured \| GMIB Assets \| Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100%
Liberty Re (Bermuda) Ltd. \| Secured \| GMIB Assets \| Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100%
Other Contract [Member]
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 437	$ 601
Other Contract [Member] \| Berkshire
Ceded Credit Risk [Line Items]
GMIB recoverables	207	283
Other Contract [Member] \| Sun Life Assurance Company of Canada
Ceded Credit Risk [Line Items]
GMIB recoverables	120	167
Other Contract [Member] \| Liberty Re (Bermuda) Ltd.
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 110	$ 151

Investments - Investments by Ca

Investments - Investments by Category (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current
Investments including assets of business held for sale		$ 1,264
Investments classified as assets of business held for sale		(344)
Investments per Consolidated Balance Sheets	$ 783	920
Long-term
Investments including assets of business held for sale		23,203
Investments classified as assets of business held for sale		(4,765)
Investments per Consolidated Balance Sheets	16,273	18,438
Total
Investments including assets of business held for sale		24,467
Investments classified as assets of business held for sale		(5,109)
Investments per Consolidated Balance Sheets	17,056	19,358
Debt securities
Current
Investments including assets of business held for sale		796
Investments per Consolidated Balance Sheets	567
Long-term
Investments including assets of business held for sale		16,162
Investments per Consolidated Balance Sheets	9,263
Total
Investments including assets of business held for sale		16,958
Investments per Consolidated Balance Sheets	9,830
Equity securities
Current
Investments including assets of business held for sale		0
Investments per Consolidated Balance Sheets	67
Long-term
Investments including assets of business held for sale		603
Investments per Consolidated Balance Sheets	604
Total
Investments including assets of business held for sale		603
Investments per Consolidated Balance Sheets	671
Commercial mortgage loans
Current
Investments including assets of business held for sale		40
Investments per Consolidated Balance Sheets	13
Long-term
Investments including assets of business held for sale		1,526
Investments per Consolidated Balance Sheets	1,557
Total
Investments including assets of business held for sale		1,566
Investments per Consolidated Balance Sheets	1,570
Policy loans
Current
Investments including assets of business held for sale		0
Investments per Consolidated Balance Sheets	0
Long-term
Investments including assets of business held for sale		1,338
Investments per Consolidated Balance Sheets	1,210
Total
Investments including assets of business held for sale		1,338
Investments per Consolidated Balance Sheets	1,210
Other long-term investments
Current
Investments including assets of business held for sale		0
Investments per Consolidated Balance Sheets	0
Long-term
Investments including assets of business held for sale		3,574
Investments per Consolidated Balance Sheets	3,639
Total
Investments including assets of business held for sale		3,574
Investments per Consolidated Balance Sheets	3,639
Short-term investments
Current
Investments including assets of business held for sale		428
Investments per Consolidated Balance Sheets	136
Long-term
Investments including assets of business held for sale		0
Investments per Consolidated Balance Sheets	0
Total
Investments including assets of business held for sale		$ 428
Investments per Consolidated Balance Sheets	$ 136

Investments - Debt Securities b

Investments - Debt Securities by Contractual Maturity Periods (Details) $ in Millions	Sep. 30, 2022 USD ($)
Amortized Cost
Due in one year or less	$ 622
Due after one year through five years	3,745
Due after five years through ten years	3,723
Due after ten years	2,544
Mortgage and other asset-backed securities	392
Total	11,026
Fair Value
Due in one year or less	596
Due after one year through five years	3,459
Due after five years through ten years	3,230
Due after ten years	2,200
Mortgage and other asset-backed securities	345
Total	$ 9,830

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($)	9 Months Ended
Investments - Narrative (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Schedule of Investments [Line Items]
Gain (loss) recognized in the income statement
Gain (loss) recognized in other comprehensive income
Gains (losses) reclassified from other comprehensive income into shareholders' net income
Equity Securities FV NI \| Product Concentration Risk \| Health Care Sector
Schedule of Investments [Line Items]
Concentration percentage	65%

Investments - Gross Unrealized

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 11,026
Allowance for Credit Loss	(56)
Unrealized Appreciation	136
Unrealized Depreciation	(1,276)
Fair Value	9,830
Amortized Cost		$ 15,775
Allowance for Credit Loss		(23)
Unrealized Appreciation		1,337
Unrealized Depreciation		(131)
Fair Value		16,958
Run-Off Settlement Annuity Business
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		2,262
Allowance for Credit Loss		(5)
Unrealized Appreciation		720
Unrealized Depreciation		(10)
Fair Value		2,967
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	304
Allowance for Credit Loss	0
Unrealized Appreciation	41
Unrealized Depreciation	(12)
Fair Value	333
Amortized Cost		287
Allowance for Credit Loss		0
Unrealized Appreciation		101
Unrealized Depreciation		(1)
Fair Value		387
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	43
Allowance for Credit Loss	0
Unrealized Appreciation	0
Unrealized Depreciation	(3)
Fair Value	40
Amortized Cost		154
Allowance for Credit Loss		0
Unrealized Appreciation		17
Unrealized Depreciation		0
Fair Value		171
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	377
Allowance for Credit Loss	0
Unrealized Appreciation	19
Unrealized Depreciation	(27)
Fair Value	369
Amortized Cost		2,468
Allowance for Credit Loss		0
Unrealized Appreciation		194
Unrealized Depreciation		(46)
Fair Value		2,616
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	9,910
Allowance for Credit Loss	(56)
Unrealized Appreciation	76
Unrealized Depreciation	(1,187)
Fair Value	8,743
Amortized Cost		12,361
Allowance for Credit Loss		(23)
Unrealized Appreciation		1,008
Unrealized Depreciation		(80)
Fair Value		13,266
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	392
Allowance for Credit Loss	0
Unrealized Appreciation	0
Unrealized Depreciation	(47)
Fair Value	$ 345
Amortized Cost		505
Allowance for Credit Loss		0
Unrealized Appreciation		17
Unrealized Depreciation		(4)
Fair Value		$ 518

Investments - Summary of Debt S

Investments - Summary of Debt Securities with a Decline in Fair Value (Details) $ in Millions	Sep. 30, 2022 USD ($) position	Dec. 31, 2021 USD ($) position
More than one year
Fair Value	$ 8,172
Total Amortized Cost	9,448
Unrealized Depreciation	$ (1,276)
Number of Issues \| position	3,686
Total Fair Value		$ 3,890
Total Amortized Cost		4,021
Total Unrealized Depreciation		$ (131)
Total Number of Issues \| position		1,886
Investment grade \| Debt securities
One year or less
Fair Value	$ 6,101
Amortized Cost	6,959
Unrealized Depreciation	$ (858)
Number of Issues \| position	1,798
Fair Value		$ 2,785
Amortized Cost		2,861
Unrealized Depreciation		$ (76)
Number of Issues \| position		909
More than one year
Fair Value	$ 720
Amortized Cost	965
Unrealized Depreciation	$ (245)
Number of Issues \| position	325
Fair Value		$ 382
Amortized Cost		412
Unrealized Depreciation		$ (30)
Number of Issues \| position		143
Below investment grade \| Debt securities
One year or less
Fair Value	$ 1,094
Amortized Cost	1,214
Unrealized Depreciation	$ (120)
Number of Issues \| position	1,307
Fair Value		$ 561
Amortized Cost		578
Unrealized Depreciation		$ (17)
Number of Issues \| position		781
More than one year
Fair Value	$ 257
Amortized Cost	310
Unrealized Depreciation	$ (53)
Number of Issues \| position	256
Fair Value		$ 162
Amortized Cost		170
Unrealized Depreciation		$ (8)
Number of Issues \| position		53

Investments - Equity Security I

Investments - Equity Security Investments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Cost
Equity securities with readily determinable fair values	$ 693
Equity securities with no readily determinable fair value	358
Total	1,051
Equity securities with readily determinable fair values		$ 257
Equity securities with no readily determinable fair value		270
Total		527
Carrying Value
Equity securities with readily determinable fair values	210
Equity securities with no readily determinable fair value	461
Total	$ 671
Equity securities with readily determinable fair values		207
Equity securities with no readily determinable fair value		396
Total		$ 603

Investments - Summary of the Cr

Investments - Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Schedule of Investments [Line Items]
Allowance for credit losses	$ (13)	$ (6)
Total	$ 1,570	$ 1,566
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.84	1.96
Average Loan-to-Value Ratio	59%	61%
Below 60%
Schedule of Investments [Line Items]
Carrying Value	$ 848	$ 560
Below 60% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.21	2.18
60% to 79%
Schedule of Investments [Line Items]
Carrying Value	$ 565	$ 883
60% to 79% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.49	1.89
80% to 100%
Schedule of Investments [Line Items]
Carrying Value	$ 107	$ 129
80% to 100% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.21	1.47
Greater than 100%
Schedule of Investments [Line Items]
Carrying Value	$ 63	$ 0
Greater than 100% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.04	0

Investments - Carrying Values o

Investments - Carrying Values of Other Long-Term Investments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Schedule of Investments [Line Items]
Other long-term investments	$ 3,639
Other long term investments		$ 3,574
Real estate investments
Schedule of Investments [Line Items]
Other long-term investments	1,231
Other long term investments		1,152
Securities partnerships
Schedule of Investments [Line Items]
Other long-term investments	2,091
Other long term investments		2,272
Other
Schedule of Investments [Line Items]
Other long-term investments	$ 317
Other long term investments		$ 150

Investments - Summary of Deriva

Investments - Summary of Derivative Instruments Held (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Designated as Hedging Instrument \| Fair Value Hedging \| Foreign currency swap contracts
Derivative [Line Items]
Notional Value	$ 1,078
Notional Value		$ 1,081
Designated as Hedging Instrument \| Fair Value Hedging \| Interest rate swap contracts
Derivative [Line Items]
Notional Value	1,500
Notional Value		750
Designated as Hedging Instrument \| Net Investment Hedging \| Foreign currency swap contracts
Derivative [Line Items]
Notional Value	460
Notional Value		526
Designated as Hedging Instrument \| Net Investment Hedging \| Foreign currency forward contracts (1)
Derivative [Line Items]
Notional Value	0
Notional Value		1,380
Not Designated as Hedging Instrument, Economic Hedge \| Foreign currency forward contracts (1)
Derivative [Line Items]
Notional Value	$ 0
Notional Value		$ 720

Investments - Realized Gains an

Investments - Realized Gains and Losses on Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investments [Abstract]
Net realized investment (losses) gains, excluding credit loss expense and asset write-downs	$ (65)	$ 44	$ (455)	$ 114
Credit loss (expense) recoveries	(16)	24	(40)	14
Net realized investment (losses) gains, before income taxes	$ (81)	$ 68	$ (495)	$ 128

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Financial assets at fair value:
Debt Securities		$ 16,958
Equity securities		207
Recurring
Financial assets at fair value:
Debt Securities	$ 9,830
Equity securities	210
Short-term investments	131
Debt Securities		16,958
Equity securities		207
Short-term investments		428
Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	340
Derivative assets		143
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0
Derivative liabilities		33
Recurring \| Swaps \| Short-term investments
Financial assets at fair value:
Derivative assets	5
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	141
Equity securities	6
Short-term investments	0
Debt Securities		147
Equity securities		16
Short-term investments		0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0
Derivative assets		0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0
Derivative liabilities		0
Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	9,185
Equity securities	204
Short-term investments	131
Debt Securities		16,046
Equity securities		160
Short-term investments		428
Significant Other Observable Inputs (Level 2) \| Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	340
Derivative assets		143
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0
Derivative liabilities		33
Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	504
Equity securities	0
Short-term investments	0
Debt Securities		765
Equity securities		31
Short-term investments		0
Significant Unobservable Inputs (Level 3) \| Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0
Derivative assets		0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0
Derivative liabilities		0
Federal government and agency
Financial assets at fair value:
Debt Securities		387
Federal government and agency \| Recurring
Financial assets at fair value:
Debt Securities	333
Debt Securities		387
Federal government and agency \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	141
Debt Securities		147
Federal government and agency \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	192
Debt Securities		240
Federal government and agency \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		0
State and local government
Financial assets at fair value:
Debt Securities		171
State and local government \| Recurring
Financial assets at fair value:
Debt Securities	40
Debt Securities		171
State and local government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		0
State and local government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	40
Debt Securities		171
State and local government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		0
Foreign government
Financial assets at fair value:
Debt Securities		2,616
Foreign government \| Recurring
Financial assets at fair value:
Debt Securities	369
Debt Securities		2,616
Foreign government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		0
Foreign government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	369
Debt Securities		2,611
Foreign government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		5
Corporate
Financial assets at fair value:
Debt Securities		13,266
Corporate \| Recurring
Financial assets at fair value:
Debt Securities	8,743
Debt Securities		13,266
Corporate \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		0
Corporate \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	8,320
Debt Securities		12,606
Corporate \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	423
Debt Securities		660
Mortgage and other asset-backed
Financial assets at fair value:
Debt Securities		518
Mortgage and other asset-backed \| Recurring
Financial assets at fair value:
Debt Securities	345
Debt Securities		518
Mortgage and other asset-backed \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Debt Securities		0
Mortgage and other asset-backed \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	264
Debt Securities		418
Mortgage and other asset-backed \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	$ 81
Debt Securities		$ 100

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - Separate Account Assets - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), , including transfers in and out of Level 3
Recurring \| Securities partnerships
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Expected liquidation period after inception			10 years

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 504
Fair Value		$ 765
Corporate and government debt securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 422
Fair Value		$ 664
Corporate and government debt securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0040
Unobservable Adjustment		0.0060
Corporate and government debt securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.1290
Unobservable Adjustment		0.1060
Corporate and government debt securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0320
Unobservable Adjustment		0.0410
Mortgage and other asset-backed securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 81
Fair Value		$ 100
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060
Unobservable Adjustment		0.0060
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0520
Unobservable Adjustment		0.0390
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0190
Unobservable Adjustment		0.0100
Other debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 1
Fair Value		$ 1

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Transfers into/(out of) Level 3
Change in unrealized gains or losses included in Other comprehensive income (loss) for assets held at the end of the reporting period	$ (33)	$ 2	$ (60)	$ (8)
Debt and Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance		854		854
Balance	512		796
Gains (losses) included in Shareholders' net income	4	3	14	(8)
(Losses) gains included in Other comprehensive income (loss)	(34)	2	(62)	(7)
Gains (losses) required to adjust future policy benefits for settlement annuities	23	1	0	(6)
Purchases, sales and settlements
Purchases	81	37	157	108
Sales	0	(36)	0	(36)
Settlements	(54)	(1)	(206)	(26)
Total purchases, sales and settlements	27	0	(49)	46
Transfers into/(out of) Level 3
Transfers into Level 3	6	58	124	181
Transfers out of Level 3	(34)	(19)	(319)	(161)
Total transfers into/(out of) Level 3	(28)	39	(195)	20
Balance	504	899	504	899
Total (losses) included in Shareholders' net income attributable to instruments held at the reporting date	$ 0	$ (3)	$ (2)	$ (3)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Values of Separate Account Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	$ 581
Non-guaranteed separate accounts	5,847
Subtotal	6,428
Guaranteed separate accounts		$ 503
Non-guaranteed separate accounts		7,870
Subtotal		8,373
Non-guaranteed separate accounts priced at NAV as a practical expedient	832
Non-guaranteed separate accounts priced at NAV as a practical expedient		842
Total		9,215
Separate account assets of business classified as held for sale		(878)
Separate account assets	7,260	8,337
Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	4,000
Non-guaranteed separate accounts		4,500
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	195
Non-guaranteed separate accounts	194
Subtotal	389
Guaranteed separate accounts		227
Non-guaranteed separate accounts		1,130
Subtotal		1,357
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	386
Non-guaranteed separate accounts	5,442
Subtotal	5,828
Guaranteed separate accounts		276
Non-guaranteed separate accounts		6,406
Subtotal		6,682
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	0
Non-guaranteed separate accounts	211
Subtotal	211
Guaranteed separate accounts		0
Non-guaranteed separate accounts		334
Subtotal		334
Significant Unobservable Inputs (Level 3) \| Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	$ 200
Non-guaranteed separate accounts		$ 300

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details) - Separate Account Assets - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 263
Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	832
Fair Value		$ 842
Securities partnerships
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	263
Securities partnerships \| Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	475
Fair Value		513
Real estate funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Real estate funds \| Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Real estate funds \| Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Real estate funds \| Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 353
Fair Value		325
Hedge funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Hedge funds \| Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Hedge funds \| Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Hedge funds \| Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 4
Fair Value		$ 4

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Realized investment losses on assets measured at fair value under certain conditions, after-tax
Realized investment gains on equity securities with no readily determinable fair value

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value \| Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 28,411	$ 35,621
Fair Value \| Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,439	1,598
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,570	1,566
Long-term debt, including current maturities, excluding finance leases	$ 31,477	$ 31,593

Variable Interest Entities (Det

Variable Interest Entities (Details) - entity	Sep. 30, 2022	Dec. 31, 2021
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	0	0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 45,922	$ 48,716	$ 47,130	$ 50,328
Other comprehensive income (loss), net of tax	72	(77)	(1,127)	(298)
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	1	(1)	(2)	(6)
Shareholders other comprehensive income (loss), net of tax	71	(76)	(1,125)	(292)
Balance	45,083	47,427	45,083	47,427
Securities and Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(285)	749	685	900
Other comprehensive income (loss) before reclassifications, before tax	(259)	59	(1,505)	(113)
Other comprehensive income (loss) before reclassifications, tax	(22)	(16)	233	9
Other comprehensive income (loss) before reclassifications, after-tax	(281)	43	(1,272)	(104)
Reclassification adjustment, tax	(3)	3	(9)	5
Net amounts reclassified from AOCI to net income	182	(11)	203	(15)
Shareholders other comprehensive income (loss), net of tax	(99)	32	(1,069)	(119)
Balance	(384)	781	(384)	781
Reclassification adjustment for losses included in Shareholders' net income (Gain on sale of businesses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net amounts reclassified from AOCI to net income	171	0	171	0
Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	14	(14)	41	(20)
Translation of foreign currencies
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications, before tax, including temporary equity	(105)	(118)	(345)	(216)
Other comprehensive income (loss) before reclassifications, tax, including temporary equity	1	(7)	(28)	(12)
Other comprehensive income (loss) before reclassifications, after-tax, including temporary equity	(104)	(125)	(373)	(228)
Reclassification adjustment, before tax	236	0	236	0
Reclassification adjustment, tax	29	0	29	0
Net amounts reclassified from AOCI to net income	265	0	265	0
Translation of foreign currencies, before tax	131	(118)	(109)	(216)
Translation of foreign currencies, tax	30	(7)	1	(12)
Other comprehensive income (loss), net of tax	161	(125)	(108)	(228)
Translation of foreign currencies attributable to noncontrolling interest
Accumulated Other Comprehensive Income (Loss) [Line Items]
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	1	(1)	(2)	(6)
Translation of foreign currencies attributable to parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(499)	(113)	(233)	(15)
Shareholders other comprehensive income (loss), net of tax	160	(124)	(106)	(222)
Balance	(339)	(237)	(339)	(237)
Postretirement benefits liability
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1,296)	(1,713)	(1,336)	(1,746)
Other comprehensive income (loss) before reclassifications, before tax	0	0	18	0
Other comprehensive income (loss) before reclassifications, tax	0	0	(4)	0
Other comprehensive income (loss) before reclassifications, after-tax	0	0	14	0
Reclassification adjustment, tax	(5)	(5)	(12)	(15)
Net amounts reclassified from AOCI to net income	10	16	36	49
Shareholders other comprehensive income (loss), net of tax	10	16	50	49
Balance	(1,286)	(1,697)	(1,286)	(1,697)
Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	17	21	50	60
Reclassification adjustment for (gains) included in Shareholders' net income (Gain on sale of businesses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	(2)	0	(2)	0
Reclassification adjustment for settlement (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	$ 0	$ 0	$ 0	$ 4

Organizational Efficiency Pla_2

Organizational Efficiency Plan - Narrative (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Charge for organizational efficiency plan (in Selling, general and administrative expenses), pre-tax	$ 0		$ 168	$ 0	$ 22	$ 0
Charge for organizational efficiency plan (in Selling, general and administrative expenses), after-tax	$ 0		119	$ 0	$ 17	$ 0
Restructuring charges, abandonment of leased assets and impairment of property and equipment			59
Restructuring charges, severance costs		$ 22	$ 109
Restructuring charge, severance costs, after-tax		$ 17

Organizational Efficiency Pla_3

Organizational Efficiency Plan - Rollforward of Accrued Liability (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Balance, December 31, 2021			$ 103
2022 payments			(65)
Second quarter 2022 charge	$ 22	$ 109
Balance, September 30, 2022		$ 103	$ 60

Leases - Operating and Finance

Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Operating leases:
Operating lease ROU assets	$ 396
Operating lease ROU assets		$ 478
Accrued expenses and other liabilities	133
Accrued expenses and other liabilities		159
Other non-current liabilities	368
Other non-current liabilities		436
Total operating lease liabilities	501
Total operating lease liabilities		595
Finance leases:
Property and equipment, gross	147	101
Accumulated depreciation	(46)	(51)
Property and equipment, net	101	50
Short-term debt	32	23
Long-term debt	69	28
Total finance lease liabilities	$ 101	$ 51
Balance sheet location of operating lease ROU assets	Other assets	Other assets
Balance sheet location of current operating lease liabilities	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Balance sheet location of non-current operating lease liabilities	Other non-current liabilities	Other non-current liabilities
Balance sheet location of non-current finance lease assets	Property and equipment	Property and equipment
Balance sheet location of current finance lease liabilities	Short-term debt	Short-term debt
Balance sheet location of non-current finance lease liabilities	Long-term debt	Long-term debt
Operating lease ROU assets, held for sale		$ 27
Operating lease liabilities, held for sale		$ 28

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Consolidated effective tax rate	20.40%	20.60%	21%	21.70%
Deferred tax assets, investments	$ 360		$ 360

Contingencies and Other Matte_2

Contingencies and Other Matters (Details)			1 Months Ended	9 Months Ended
Contingencies and Other Matters (Details)	Mar. 31, 2022 USD ($)	Apr. 19, 2016 claim	Mar. 31, 2016 USD ($)	Sep. 30, 2022 USD ($)
Guaranty Fund Assessments
Commitments And Contingencies [Line Items]
Loss contingency accrual provision
Litigation Matters and Regulatory Matters
Commitments And Contingencies [Line Items]
Reserves for litigation matters, pre-tax
Express Scripts Litigation with Elevance \| Judicial Ruling \| Pricing Concessions
Commitments And Contingencies [Line Items]
Damages sought by Elevance	$ 14,800,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Pricing Concessions Through Remaining Contract Term
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 13,000,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Pricing Concessions After Remaining Term of Agreement
Commitments And Contingencies [Line Items]
Damages sought by Elevance			1,800,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Damages for Service Issues
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 150,000,000
Express Scripts counterclaims against Elevance
Commitments And Contingencies [Line Items]
Number of counts dismissed \| claim		2
Number of counts \| claim		6
Indemnification obligations
Commitments And Contingencies [Line Items]
Liability for guarantees				0
Retiree and Life Insurance Benefits \| Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure				420,000,000
Assets maintained by employers (minimum)				420,000,000
Liability for guarantees				$ 0

Segment Information - Summary o

Segment Information - Summary of Special Items (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
After-tax
Integration and transaction-related costs (Selling, general and administrative expenses)	$ 23		$ (35)	$ 86	$ 1
Charge for organizational efficiency plan (Selling, general and administrative expenses)	0	$ 119	0	17	0
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	0		0	(20)	(21)
(Gain) on sale of business	(1,388)		0	(1,388)	0
Debt extinguishment costs	0		0	0	110
Total impact from special items	(1,365)		(35)	(1,305)	90
Before-tax
Integration and transaction-related costs (Selling, general and administrative expenses)	24		13	112	58
Charge for organizational efficiency plan (Selling, general and administrative expenses)	0	$ 168	0	22	0
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	0		0	(28)	(27)
(Gain) on sale of business	(1,735)		0	(1,735)	0
Debt extinguishment costs	0		0	0	141
Total impact from special items	$ (1,711)		$ 13	$ (1,629)	$ 172

Segment Information - Summarize

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenues from customers	$ 45,076		$ 43,820	$ 133,822	$ 127,221
Net investment income (loss)	204		468	943	1,169
TOTAL REVENUES	45,280		44,288	134,765	128,390
Net realized investment results from certain equity method investments	80		22	134	12
Adjusted revenues	45,360		44,310	134,899	128,402
Depreciation and amortization				2,202	2,180
Income before income taxes	3,491		2,059	7,025	5,470
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(22)		(16)	(54)	(39)
Net realized investment (gains) losses	161		(46)	629	(116)
Amortization of acquired intangible assets	460		501	1,419	1,499
Special items
Integration and transaction-related costs	24		13	112	58
Charge for organizational efficiency plan	0	$ 168	0	22	0
(Benefits) charges associated with litigation matters	0		0	(28)	(27)
(Gain) on sale of business	(1,735)		0	(1,735)	0
Debt extinguishment costs	0		0	0	141
Pre-tax adjusted income (loss) from operations	2,379		2,511	7,390	6,986
Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	34,670		32,668	100,675	93,640
Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	10,328		10,283	31,411	30,971
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	78		869	1,736	2,610
Operating Segments \| Evernorth
Segment Reporting Information [Line Items]
Net investment income (loss)	25		4	51	12
TOTAL REVENUES	35,698		33,614	104,147	96,826
Net realized investment results from certain equity method investments	0		0	0	0
Adjusted revenues	35,698		33,614	104,147	96,826
Income before income taxes	1,200		1,074	3,114	2,752
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(17)		(10)	(41)	(21)
Net realized investment (gains) losses	0		0	0	4
Amortization of acquired intangible assets	442		484	1,329	1,449
Special items
Integration and transaction-related costs	0		0	0	0
Charge for organizational efficiency plan				0
(Benefits) charges associated with litigation matters				0	0
(Gain) on sale of business	0			0
Debt extinguishment costs					0
Pre-tax adjusted income (loss) from operations	1,625		1,548	4,402	4,184
Operating Segments \| Cigna Healthcare
Segment Reporting Information [Line Items]
Net investment income (loss)	101		333	545	772
TOTAL REVENUES	11,096		11,200	33,771	33,426
Net realized investment results from certain equity method investments	80		22	134	12
Adjusted revenues	11,176		11,222	33,905	33,438
Income before income taxes	879		1,110	2,943	3,266
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(1)		(1)	(2)	(2)
Net realized investment (gains) losses	158		(73)	542	(163)
Amortization of acquired intangible assets	17		10	89	36
Special items
Integration and transaction-related costs	0		0	0	0
Charge for organizational efficiency plan				0
(Benefits) charges associated with litigation matters				0	0
(Gain) on sale of business	0			0
Debt extinguishment costs					0
Pre-tax adjusted income (loss) from operations	1,053		1,046	3,572	3,137
Operating Segments \| Other Operations
Segment Reporting Information [Line Items]
Net investment income (loss)	75		131	344	385
TOTAL REVENUES	153		1,000	2,080	2,995
Net realized investment results from certain equity method investments	0		0	0	0
Adjusted revenues	153		1,000	2,080	2,995
Income before income taxes	1,752		196	2,134	630
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(4)		(5)	(11)	(16)
Net realized investment (gains) losses	3		27	87	43
Amortization of acquired intangible assets	1		7	1	14
Special items
Integration and transaction-related costs	0		0	0	0
Charge for organizational efficiency plan				0
(Benefits) charges associated with litigation matters				0	0
(Gain) on sale of business	(1,735)			(1,735)
Debt extinguishment costs					0
Pre-tax adjusted income (loss) from operations	17		225	476	671
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net investment income (loss)	3		0	3	0
TOTAL REVENUES	(1,667)		(1,526)	(5,233)	(4,857)
Net realized investment results from certain equity method investments	0		0	0	0
Adjusted revenues	(1,667)		(1,526)	(5,233)	(4,857)
Income before income taxes	(340)		(321)	(1,166)	(1,178)
Special items
Pre-tax adjusted income (loss) from operations	(316)		(308)	(1,060)	(1,006)
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	0		0	0	0
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0		0	0	0
Net realized investment (gains) losses	0		0	0	0
Amortization of acquired intangible assets	0		0	0	0
Special items
Integration and transaction-related costs	24		13	112	58
Charge for organizational efficiency plan				22
(Benefits) charges associated with litigation matters				(28)	(27)
(Gain) on sale of business	0			0
Debt extinguishment costs					141
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(1,670)		(1,526)	(5,236)	(4,857)
Intersegment Eliminations \| Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	(1,003)		(942)	(3,421)	(3,174)
Intersegment Eliminations \| Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	(667)		(584)	(1,815)	(1,683)
Intersegment Eliminations \| Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ 0		$ 0	$ 0	$ 0

Segment Information - Revenue f

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Premiums	$ 9,586	$ 10,275	$ 30,368	$ 30,812
Total revenues from external customers	45,076	43,820	133,822	127,221
Intersegment Eliminations
Revenue from External Customer [Line Items]
Premiums	2	(3)	0	(6)
Total revenues from external customers	(1,670)	(1,526)	(5,236)	(4,857)
Operating Segments \| Divested international businesses
Revenue from External Customer [Line Items]
Premiums	0	800	1,500	2,418
Operating Segments \| Other
Revenue from External Customer [Line Items]
Premiums	76	61	219	169
Evernorth
Revenue from External Customer [Line Items]
Total revenues from external customers	34,670	32,668	100,675	93,640
Evernorth \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(1,003)	(942)	(3,421)	(3,174)
Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	10,328	10,283	31,411	30,971
Cigna Healthcare \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(667)	(584)	(1,815)	(1,683)
Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	78	869	1,736	2,610
Other Operations \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	0	0	0	0
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenues	32,762	31,013	95,431	89,085
Pharmacy revenues \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(1,034)	(972)	(3,349)	(3,326)
Network revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	16,583	16,488	48,221	47,792
Home delivery and specialty revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	15,583	13,796	45,550	39,911
Other revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,630	1,701	5,009	4,708
Cigna Healthcare \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	9,508	9,417	28,649	28,231
Insured \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	3,821	3,591	11,312	10,692
Stop loss \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,384	1,225	4,053	3,613
Other \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	353	320	1,065	938
Medicare Advantage \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,949	2,079	6,080	6,287
Medicare Part D \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	240	315	986	1,175
Other \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,029	1,241	3,007	3,606
International Health \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	732	646	2,146	1,920
Total fees and other revenues
Revenue from External Customer [Line Items]
Revenues	2,728	2,532	8,023	7,324
Total fees and other revenues \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(638)	(551)	(1,887)	(1,525)
Fees \| Evernorth \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,875	1,623	5,289	4,393
Fees \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,530	1,433	4,504	4,292
Fees \| Other Operations \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	0	4	9	14
Other revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	$ (39)	$ 23	$ 108	$ 150

Segment Information - Narrative

Segment Information - Narrative (Details) - USD ($) $ in Billions	Sep. 30, 2022	Dec. 31, 2021
Pharmacy Benefits Management Services \| Guarantees
Loss Contingencies [Line Items]
Guarantee liability	$ 1.1	$ 1.1